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Inter-observer Agreement in Diagnosing Non-Melanoma Skin Cancer
M Mogensen1, BM Nurnberg2 and GBE Jemec1
1Department of Dermatology, Roskilde Hospital, University of Copenhagen,
Denmark and 2Department of Pathology, Roskilde Hospital, University of
Copenhagen, Denmark
Introduction. The reference standard in non-melanoma skin cancer (NMSC)
diagnosis and cancer diagnosis in general, is biopsy and histopathological
assessment from a clinical suspicious skin lesion. Despite of this biopsy does not
have sensitivity and specificity approaching 100%. Determining diagnostic
accuracy of the reference standard itself is hampered by the fact, that there are
several classification systems for NMSC. Because all diagnostic test of NMSC
should be compared to histopathology, it is of prime importance to reach consensus
on diagnostic criterias, and perform inter-observer accuracy studies.
Methods. In this prospective inter-observer study of diagnostic accuracy among
dermatopathologist, the inter-observer concordance will be estimated among 3
dermatopathologists, one located in Roskilde Hospital, University of Copenhagen,
one located in Japan and one in Marshfield,US. The same set of 50 NMSC
histopathology slides will be distributed to the doctors involved. All doctors will be
blinded to the others results.
Results. The concordance rates will be presented and will be incorporated in our
diagnostic accuracy study of optical coherence tomography in NMSC diagnosis.
Discussion. Unfortunately the naked eye cannot always determine whether a
suspicious lesion is a NMSC. Since optimal management of skin malignancies relies
on early and accurate diagnosis, proper diagnostic research strategies must be
applied to the evaluation of all diagnostic methods. It is of prime importance to
consider the precision of histopathology diagnosis, as it is considered the reference
standard for all other diagnostic procedures in NMSC.
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Intra-Individual Comparison of MAL-PDT and Cryotherapy in Subjects
with Actinic Keratoses: A Multicentre, Randomized, Controlled Study
C Morton1, S Campbell2, G Gupta3, S Keohane4, J Lear5, I Zaki6, S Walton7, N
Kerrouche8, G Thomas8 and P Soto8 on behalf of the Aktion Investigators*
1Falkirk Royal Infirmary, Falkirk, Scotland, 2Royal Cornwall Hospital, Cornwall,
UK, 3Monklands Hospital, Lanarkshire, UK, 4St Mary’s Hospital, Portsmouth,
Hampshire, UK, 5Manchester Royal Infirmary, Manchester, UK, 6Heart of England
NHS Foundation Trust, West Midlands, UK, 7Princess Royal Hospital, Hull And
East Yorkshire Hospitals, Hull, UK and 8Galderma, Sophia Antipolis, France
Background: Actinic keratoses (AK), the most common pre-malignant skin
condition, can represent a treatment and cosmetic outcome challenge on typical
sun-exposed highly visible body sites.
Aim: to compare the lesion response and subject preference of topical MAL-PDT
(methyl aminolevulinate – Photodynamic therapy) with cryotherapy for the
treatment of AK.
Methods: Subjects received both 1 treatment session of MAL-PDT and a double
freeze-thaw cryotherapy, repeated after 3 months if incomplete response; the
treatments had been randomly allocated to either side of the face/scalp.
Results: A total of 119 subjects with 1501 lesions were included in the study. After
the first treatment at week 12, the percent lesion reduction from baseline was
significantly better with MAL-PDT than with cryotherapy (84.4% versus 74.5%;
po0.001). At week 24, further to re-treatment when necessary, both treatment
groups showed similarly high rates of cured lesions (percent lesion reduction from
baseline: 89% for MAL-PDT versus 86% for cryotherapy). Subject and investigator
preference as well as cosmetic outcome favored MAL-PDT. Both treatment
regimens were safe and well tolerated.
Conclusion: The present study shows that, when treated with both MAL-PDT and
cryotherapy, subjects significantly prefer MAL-PDT treatment for AK. MAL-PDT is
an attractive treatment option for AK, with comparable efficacy and superior
cosmetic outcome compared to double freeze-thaw cryotherapy.
P03
Treatment of Actinic Cheilitis with Tazarotene 0.05% Gel
C Mordenti, L Diluvio, I De Simoni, E Campione, I Carboni and S Chimenti
Department of Dermatology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Actinic cheilitis is a common condition, most often observed on the vermilion
border of the lower lip. Multiple treatment modalities have been reported including
PDT, cryotherapy and surgical excision. Tazarotene is an acetylenic retinoid
selective for retinoic acid receptor-b and -g isotypes. It has been proposed for
treating different skin disorders, such as psoriasis, acne, photoaging, and it also
shows experimental anti-cancer activity. Tazarotene acts through its free-acid form,
tazarotenic acid, but its mechanisms of action in cancer regression are not well
investigated. Preliminary clinical experiences suggested that tazarotene is an
alternative option for the treatment of non-melanoma as well as lentigo maligna
skin cancers. We describe 3 male patients (age ranged between 57 and 76 years
old) with actinic cheilitis on the lower lip, treated with topical tazarotene 0.05%
gel. The agent was applied, not occluded, at bed time, overnight. After 2 months of
treatment, remarkable reduction of the lesion was already observed and complete
remission was obtained after 4 months. Tazarotene was well tolerated from all
patients who only complained slight burning and erythema, diminishing after
topical application of lenitive cream and reducing during therapy. During 18
months of subsequent follow-up, no signs of recurrences were observed. At present
the patients are applying tazarotene once weekly per months. In conclusion, this
preliminary observation suggests that topical administration of tazarotene 0.05%
might represent a new treatment option in patients affected by actinic cheilitis
because of efficacy, tolerability and compliance.
P04
Photodynamic Therapy for the Treatment of Actinic Cheilitis
R Rossi, G Bani Assad, M Mori and T Lotti
University Unit of Dermatology and Physiotherapy, University of Florence,
Florence, Italy
Actinic cheilitis is a common disease of the labial skin, mostly of the lower lip. As
same as actinic keratosis (AK) of the skin, actinic cheilitis (AK of the lip) is
considered a pre-malignant lesion that may undergo malignant transformation into
invasive squamous cell carcinoma (SCC). The main risk factor for developing
actinic cheilitis seems to be solar exposure, with a higher incidence in fair-skinned
people (Fitzpatrick skin phototype I–II). The lower lip is mostly affected because of
the anatomic proximity to the solar rays. Other factors include tobacco use, lip
irritation, poor oral hygiene and ill-fitting dentures. Patients with actinic cheilitis
should have an aimed treatment to avoid and prevent a malignant transformation
into invasive SCC, by means of destroying or removing the damaged epithelium.
The major therapeutic approaches include, surgical excision (vermiliorectomy)
cryotherapy, electrodesiccation, CO2 Laser ablation, 5-fluorouracil cream and
imiquimod 5% cream. Recently, photodynamic therapy (PDT) has been introduced
as a therapeutic modality for epithelial skin tumours, revealing high efficacy and
satisfactory outcomes in cutaneous actinic keratosis and superficial/nodular basal
cell carcinoma (BCC) but there are only few reports on PDT as therapeutic
approach for actinic cheilitis published till now. The target of our study was to
evaluate the efficacy and tolerability of photodynamic therapy in actinic cheilitis,
using as topical photosensitizing agent a methyl-ester of aminolevulinic acid;
methyl-aminolevulinate (MAL). Our results showed that PDT seems to be the ideal
treatment for actinic cheilitis and other Aks, specially in exposed parts such as the
face, joining tolerability, clinical efficacy and excellent cosmetic outcome. It might
be also an alternative for patients who refuse surgical procedures or whenever the
surgery is contraindicated, as in selected group of patients with systemic diseases,
such as blood abnormalities, immunosuppresion (organ transplants), or severe
organ dysfunction.
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MAL-PDT in ‘‘Difficult-to-Treat’’ Basal Cell Carcinoma, an Australian
Study: 48 Month Follow-Up Data
C Vinciullo1, T Elliott2 and D Francis3
1Dermatology Surgery and Laser Centre, South Perth, Australia, 2Fremantle
Hospital, Fremantle, Western Australia, Australia and 3Southeastern Dermatology,
Carina, Brisbane, Queensland, Australia
Background: Conventional therapies sometimes pose a clinical challenge for the
treatment of basal cell carcinoma (BCC). Photodynamic therapy (PDT) with methyl-
aminolevulinate (MAL-PDT) is a non-invasive treatment for non-melanoma skin
cancer with evidence of long-term efficacy.
Objectives: To assess complete lesion response at 3 months, lesion recurrence rate
at 48 months and overall cosmetic outcome in a specific patient population with
‘difficult- to-treat BCC’ treated with MAL-PDT.
Methods: Included were subjects with high-risk BCC, i.e. large lesions, located in
mid-face or ears, or at high risk of surgical complications (e.g. anticoagulant
medication or cardiac risk factors). The subjects received a cycle of 2 treatment
sessions with MAL-PDT 1 week apart, according to the standard treatment
procedure. In case of non-complete response after 3 months, the lesions were
retreated with a second cycle of 2 sessions. Lesion complete response was assessed
at month 3 after the last treatment, and lesion recurrence rate was assessed at
months 12, 24, 36 and 48.
Results: Ninety-five (95) subjects with 148 lesions were included in the PP analysis.
Three months after treatment 89% of all lesions had histologically verified CR. Of
these lesions, 8% recurred within 12 months, 15% within 24 months, 18% within
36 months and 20% within 48 months. The overall cosmetic outcome at 48 months
as assessed by the investigators was rated excellent or good in 89% of subjects in
complete response.
Conclusion: MAL-PDT is a suitable treatment for BCC patients that would otherwise
require extensive surgery with poor cosmetic outcome or who are at high risk of
surgical complications.
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A Randomized European Comparison of MAL-PDT and Excision Surgery
in Nodular Basal Cell Carcinoma: Results From a 60 Month Follow-Up
Study
LE Rhodes1, M De Rie2, Y Enstro¨m3, R Groves4, T Morken5, V Goulden6, G Wong1,
JJ Grob7, S Varma8 and P Wolf9
1Photobiology Unit, Dermatological Sciences, University of Manchester, Hope
Hospital, Salford, Manchester, UK, 2Academic Medical Centre, Amsterdam, The
Netherlands, 3NA¨L, Trollha¨ttan, Sweden, 4University College London, London, UK,
5Haukeland Hospital, Bergen, Norway, 6Leeds General Infirmary, Leeds, UK,
7Hoˆpital Sainte-Marguerite, Marseille, France, 8University Hospital, Cardiff, UK
and 9Graz University Hospital, Graz, Austria
Background: Photodynamic therapy with methyl aminolevulinate (MAL-PDT) is an
approved non-invasive treatment for nodular basal cell carcinoma (nBCC).
Objective: To report the results of a 60-month follow-up study comparing MAL-
PDT with standard excision surgery in nBCC.
Methods: Adult subjects with primary nBCC were treated with MAL-PDT (n¼ 52) or
excision surgery (n¼ 49). PDT was performed twice, 7 days apart, with MAL
160 mg/g cream and 75 J/cm2 red light (570–670 nm) after lesion surface
preparation. Patients with non-complete lesion response to MAL-PDT at 3 months
were re-treated. Primary endpoint was lesion clearance at 3 months and secondary
endpoints were lesion recurrence rate and cosmetic outcome assessed during 60
months post-treatment.
Results: A total of 97 subjects with 105 lesions were included. Complete lesion
response rates at 3 months did not differ significantly between groups: 98% with
surgery vs 91% with MAL-PDT. At 60 months follow-up, the lesion recurrence rate
was 4% in the surgery group and 14% in the MAL-PDT group. With MAL-PDT, all
recurrences had appeared within 3 years. The investigator- rated overall cosmetic
outcome for patients in complete response was ‘excellent’ or ’good’ in 87% of
MAL-PDT subjects versus 53% in the surgery group.
Conclusion: The results of this 5-year follow up comparing excision surgery to MAL-
PDT demonstrated that MAL-PDT is an effective treatment for nBCC. Although
recurrences appear more common with MAL-PDT than with surgery, MAL-PDT
offers the benefit of non invasiveness, rapid healing and better cosmetic outcome.
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MAL-PDT Versus Cryotherapy for Treatment of Primary Superficial
Basal Cell Carcinoma: Results of a Five Years Prospective Randomized
Trial
N Basset-Seguin1, S Ibbotson2, L Emtestam3, M Tarstedt4, C Morton5, M Maroti6, P
Calzavara-Pinton7, S Varma8, R Roelandts9, P Wolf10, O Saksela11 and I Rosdahl12
1St. Louis Hospital, Paris, France, 2Ninewells Hospital, Dundee, UK, 3Huddinge
Hospital, Stockholm, Sweden, 4Oˆrebro Hospital, Oˆrebro, Sweden, 5Falkirk Royal
Infirmary, Falkirk, UK, 6Ryhov County Hospital, Jo¨nko¨ping, Sweden, 7Brescia
University Hospital, Brescia, Italy, 8Cardiff University Hospital, Cardiff, UK,
9Leuven University Hospital, Leuven Belgium, 10Graz University Hospital, Graz,
Austria 11Helsinki University Hospital, Helsinki, Finland and 12Linko¨ping
University Hospital, Linko¨ping, Sweden
Background: Photodynamic therapy using topical methyl aminolevulinate (MAL-
PDT is an approved procedure for the treatment of superficial basal cell carcinoma
(sBCC).
Aim: To compare MAL-PDT with cryotherapy for the treatment of primary sBCC.
Methods: This was a multicentre, randomized parallel-group study; with five year
follow up. A total of 118 with histologically verified sBCC were treated with MAL-
PDT (n¼60) or cryotherapy (n¼58). A single MAL-PDT treatment session was
conducted. Cryotherapy was applied in 2 freeze-thaw cycles, using liquid nitrogen
spray. In subjects with non complete response at 3 months, treatment was repeated
with either 2 consecutive MAL-PDT sessions 7 days apart or double-freeze thaw
cryotherapy. Lesion complete response was evaluated at 3 months; lesion
recurrence and cosmetic outcome were followed up for 5 years.
Results: Lesion complete response rates at month 3 after the last treatment did not
differ much between the 2 groups 97% for MAL-PDT vs 95% for cryotherapy. The
cumulative recurrence rate after 60 months of follow-up was 22% for MAL-PDT
with no new recurrences after 36 months and 20% for cryotherapy. At 60 months
notably more subjects were rated by the investigators as having ‘‘excellent cosmetic
outcome’’ with MAL-PDT than with cryotherapy (56% vs 14%).
Conclusion: This five-year prospective controlled study demonstrated that lesion
recurrence rate with one MAL-PDT treatment session was comparable to double
freeze-thaw cryotherapy for the treatment of superficial BCC, and provided a
remarkably better cosmetic outcome.
P08
MAL-PDT for the Treatment of Multiple Basal Cell Carcinomas in a
Patient with Gorlin-Goltz Syndrome
D Fai
Phototherapy Unit of Dermatology Service, AUSL LE2, Gagliano del Capo, Maglie,
Italy
Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome
(NBCCS), is an autosomal dominant inherited disorder which is characterised by
the development of multiple maxillary keratocysts and/or basal cell carcinomas
(BCC). MAL-PDT was used for the treatment of multiple BCC in a 43 year-old male
with NBCCS, who presented with numerous lesions on the face and the trunk and
recurrences of BCC previously treated with cutaneous flap transplantations.
Complete response was obtained in all the treated lesions, with the exception of
a pigmented BCC. MAL-PDT actually represents a valid treatment for ’difficult-to-
treat’ BCC, including those associated with NBCCS, because it is an effective and
safe option, causing excellent cosmetic results and minimal discomfort.
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Topical Immunotherapy with Imiquimod 5% for Eyelid Nodular Basal
Cell Carcinoma
MA Blasia, D Giammariaa and E Balestrazzib
aDepartment of Ophthalmology, University of L’Aquila, Italy and bDepartment of
Ophthalmology, Catholic University of Rome, Italy
Purpose: To evaluate the efficacy and safety of topical Imiquimod 5% cream for the
treatment of eyelid basal cell carcinoma (BCC).
Methods: Imiquimod 5% cream was applied topically once daily, three days a
week for eight-fifteen weeks, in three patients affected by eyelid nodular BCC.
Patients were followed up clinically, with slit lamp examination, for evidence of
tumor disappearance or recurrence, and local and systemic side effects.
Results: Complete response was obtained in all patients. No severe local side
effects were observed. Patients did not show any local recurrence after a mean
follow-up of 17.3 (range: 8–22) months.
Conclusions: Topical Imiquimod 5% cream seems to be an effective and safe
treatment modality for eyelid nodular basal cell carcinoma, but further long-term
studies are needed.
P10
Clinical Applications of Methyl Aminolevulinate Photodynamic Therapy
(MAL-PDT) for the Treatment of Non Melanoma-Skin Cancers
M Papoutsaki, M Teoli, R Saraceno, E Paterno`, A Iliopoulou, A Costanzo and
S Chimenti
Department of Dermatology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Photodynamic therapy (PDT) is a developing approach to the treatment of cancer
and other diseases that involves the use of light to activate photosensitizer
molecules. The easy access of skin to light-based therapy has led to successfully
apply PDT in dermatology. Topical agents such as methyl aminolevulinate (MAL)
may be used for the PDT, as it acts as powerful photosensitiser. There is
considerable evidence that topical MAL-PDT is a highly effective therapy for the
treatment of non-melanoma skin cancers (not morphoeic BCCs, non-hyperkeratotic
actinic keratoses). We evaluated the efficacy of MAL-PDT for the treatment of
actinic keratoses (AC), basal cell carcinomas (BCC), actinic cheilitis, and squamous
cell carcinomas (SCC). Our study included 37 patients affected by not morphoeic
BCCs (62 lesions), 64 patients presenting actinic keratoses, 4 patients with actinic
cheilitis and 3 patients with SCC. In the majority of these patients lesions were
recurrent and had been previously treated either with surgical excision, or
cryotherapy or medical theraby (imiquimod, tazarotene, sodium diclofenac).
Patients had an average of 3 PDT sessions, every two weeks. Adverse events, such
as erythema, edema and crust formation, were mild to moderate, and treatment was
well tolerated by all patients. The results obtained are discussed. Our experience
seems to indicate that MAL-PDT is highly efficacious in the treatment of BCC,
actinic keratoses, SCC and actinic cheilitis. Moreover topical MAL-PDT offers the
advantage of tumor specificity, preservation of function and good cosmetic result,
in particular in more extensive lesions.
P11
Surgical Management of Basal Cell Carcinoma of the Lid. Report of a
Case
F Martı`n Rodrı´guez*, N Olivier Pascual**, R Pe´rez Domı´nguez**, O Ya´n˜ez
Ferna´ndez***, JL Martı´n***, A Berciano*** and F Marcos***
*Dermatology, Fundacio´n Hospital Verı´n, Ourense, Spain, **Ophthalmology,
Fundacio´n Hospital Verı´n, Ourense, Spain and ***General Practitioner
Lid reconstruction is often a challenge for surgeons. General condition of patients
and not only esthetical and functional considerations should be carefully studied
for each case. We present an extensive full-thickness basal cell carcinoma affecting
lower lid, including lid margin and medial cantus in a 93 years old woman affected
by senile dementia that needs general anaesthesia for surgery. We discuss the
different approaches for its econstruction. Tenzel semicircular flap was chosen,
despite other techniques such as Houges tarsoconjunctival flap, provides better
functional result because of a correct tarsal support, but needs a second surgery for
opening the flap, or Z-plastics and transposed or advancement flaps that gives
better esthetical results but in such an extensive lesion could have functional
problems and can not give support for the medial canthus. In this case one-step
surgery was the most important consideration, followed by functional considera-
tions (preserve tarsal rest and use it to create a new medial cantus) and very far by
esthetical considerations.
P12
Imaging Methyl Aminolevulinate-Fluorescence of Basal Cell Carcinoma
with a New Photographic System
L Mavilla, G Malara, G Moretti, M Lo Re, C Sciarrone and A Pugliesi Guerra
UO. Dermatologia, Papardo Hospital, Messina, Italy
Fluorescence diagnosis (FD) in dermatology represents a promising procedure for
the in vivo non-invasive diagnosis of neoplastic tissue, the definition of the lesion
borders and the follow-up of the treated area. Methyl aminolevulinate (Metvix –
Galderma) is a new topical agent with very high tumor selectivity for use in
photodynamic therapy (PDT). The new photographic system (Anthology – Deka)
uses the combination of a special software that allows to digitally manage the UV
shooting sessions and a column stand with standard spacers (20, 35 and 50 cm) to
actuate the repositioning of the patient and the photographic setting when patient is
recumbent. It uses a camera remote control system for every focussing operation,
selection of parameters, zoom and shooting directly from the PC; the shooting
parameters can be store and set directly by the software to ensure the
reproducibility. The preview of the shot will be displayed on the monitor of PC
and the superimposing of a reference image with the preview of the shot lets to
carry out a complete repositioning of the pictures, also for situations that are
difficult to reproduce like hands and arms. The system manages a special Twin UV
flash (360–410 nm) and a Twin White lighting, to actuate double standardized and
superimposed shots of the subject in visible lighting and UV to highlight the
distribution of externally applied fluorophores without the need to darken the entire
room, like is used to do with Wood light. Limits and perspectives will be illustred in
the poster.
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A Randomised, Placebo-Controlled, European Study Comparing MAL-
PDT with Cryotherapy and 5-Fluorouracil in Subjects with Bowen’s
Disease
CA Morton1, M Horn2, J Leman1, B Tack3, C Bedane4, M Tjioe5, S Ibbotson6, D
Khemis7 and P Wolf3
1Falkirk, Scotland, 2Graz, Austria, 3Caen, France, 4Limoges, France, 5Nijmegen,
Netherlands, 6Dundee, Scotland and 7Nice, France
Background: Methyl aminolevulinate (MAL) is a topical agent approved in Europe
for the photodynamic therapy of actinic keratosis, basal cell carcinoma and more
recently, Bowen’s disease.
Objectives: To compare efficacy and safety of MAL-PDT with placebo or with
physician’s choice of either cryotherapy or 5-fluorouracil (5-FU).
Methods: 225 patients with 275 lesions were treated with either MAL-PDT (2
treatment sessions 1 week apart (n¼ 96)), placebo-PDT (n¼ 17), cryotherapy
(n¼82) or 5-FU (n¼ 30). PDT with 160 mg/g MAL or placebo cream used a 3 h
application time and broadband red light (570 – 670 nm, total light dose 75 J/cm2).
Cryotherapy used liquid nitrogen spray, single freeze-thaw, and 5-FU was applied
for 4 weeks. Lesion response and cosmetic outcome were assessed 3 and 24
months after the last treatment.
Results: Three months after last treatment, lesion complete response rates were
93% with MAL-PDT, compared to 21% with placebo-PDT, 86% with cryotherapy
and 83% with 5-FU. The 24 month response rate was 68% (76/111 lesions) for
MAL-PDT, 11% (2/9) for placebo, 60% (51/85) for cryotherapy and 59 % (17/29) for
5-FU. MAL-PDT demonstrated a superior cosmetic result versus cryotherapy as
evaluated both by the investigator. Adverse events were of shorter duration with
MAL-PDT than with either other standard treatment.
Conclusion: MAL-PDT is significantly more efficacious than placebo-PDT and
similar to standard non-surgical treatments. It also provides excellent cosmetic
results and less down-time.
P14
MAL-PDT in ‘‘Difficult To Treat’’ Bowen’s Disease
S Cavicchini, D Moretti, C Tanzi and A Tourlaki
UO Dermatologia 1 Fondazione Policlinico, Mangiagalli, Regina Elena IRCCS,
Milano
Bowen’s disease (BD) is an in-situ squamous cell carcinoma affecting predomi-
nately old aged patients. Topical photodynamic therapy (PDT) is a non-invasive
treatment approved for superficial non-melanoma-skin-cancer (NMSC) based on
activation of a photosensitizer by light and resulting in selective destruction of
abnormal tissues. Methyl aminolevulinate (MAL) is a derivative of 5-aminolevulinic
acid (ALA) with improved lesional selectivity and probable reduction in pain during
illumination. Preliminary studies have demonstrated the good response rate of BD
to MAL-PDT. This study wanted to investigate the efficacy, safety and cosmetic
outcome of MAL-PDT in BD patients with large lesion size or at high risk of surgical
complications. Twenty Caucasian patients entered this prospective, open-label,
non comparative study after proved biopsy for BD. MAL-PDT was performed giving
2 treatments 1 week apart. MAL cream 160 mg/g was applied after light skin
curettage 3 h prior to illumination with red light (light dose of 75 J/cm2 wavelength
635 nm). The clinical and cosmetic response was evaluated 3-6-12 months after.
Complete clinical clearance with excellent cosmetic outcome was obtained in all
the patients and no recurrence was detected. Moderate to severe burning and
stinging were the side effects reported by all the patients during illumination time
MAL-PDT proved to be an excellent choice to treat BD in old age in ‘difficult to
treat’ situations which require a problematical approach.
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MAL-PDT as Adjuvant Treatment for Extramammary Paget’s Disease
S T’Kint and D Roseeuw
Department of Dermatology, Free University Brussels, Az-Vub, Belgium
A 64 year-old female patient with Crohn’s disease was diagnosed histologically
with extramammary Paget’s disease of the perivulvar and the peri-anal region. A
complete check-up revealed no concomitant malignancy. Margin delineation with
methyl aminolevulinate (MAL) was performed prior to surgery and showed
fluorescence margins extending beyond the clinical borders. Punch biopsies for
mapping were all positive for EMPD. The patient underwent wide local surgical
excision with VY-plasty. However, complete removal of the EMPD could not be
obtained without compromising the function and cosmetic outcome in this patient.
Adjuvant photodynamic therapy (PDT) was conducted with topical methyl
aminolevulinate (MAL) and red light at two- week interval sessions. After 4
sessions, MAL was applied for fluorescence mapping, to control disease clearance.
Although there was no remaining fluorescence, punch biopsies were taken showing
no more evidence of the EMPD. After a follow-up of 14 months, the patient
remained disease free. In our experience, the multimodal approach with Mohs
Micrographic surgery and adjuvant MAL-PDT improves the cure rate with minimal
tissue destruction. Tumour fluorescence mapping with MAL is a useful method for
border delineation and can be used to control disease clearance.
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Imiquimod Cream for the Treatment of Non-Melanoma Skin Cancers
E Campione, A Di Stefani, L Diluvio, EJ Paterno`, A Zangrilli and L Bianchi
Department of Dermatology, University of Rome, ‘‘Tor Vergata’’, Rome, Italy
Imiquimod is an immune modifier with antiviral and antitumor action. Therapeutic
effects of imiquimod are correlated with increased production of numerous T-
helper-1 cytokines. Imiquimod stimulates natural killer cells, the proliferation of B
lymphocytes and the migration of Langerhans cells from epidermis to satellite
lymph nodes. Recently it was shown that imiquimod has a direct pro-apoptotic
activity against tumour cells through Bcl-2-dependent release of cytochrome-c and
caspase activation. We report our clinical experience on the therapeutic efficacy
and safety of imiquimod cream 5% in a series of several non-melanoma skin
cancers (NMSC): actinic keratoses (160), primitive and recurrent superficial (100)
and nodular (30) basal cell carcinomas (BCC) and keratoacanthomas (10). The
lesions were studied and followed by clinical, dermoscopic and histopathological
investigations. The drug was locally applied, at bed time, 5 consecutive days for up
to 16 weeks. Our results displayed complete remission in all the superficial BCC
and in 10 nodular BCC. We obtained a partial remission (reduction of 4 50% of
diameter or thickness) in 20 nodular BCC. No relapses were observed after 36
months of follow-up. Complete remission after 6 weeks of treatment was observed
in all the actinic keratoses enrolled. After a follow-up of 30 months all patients were
in remission. All the keratoacanthomas treated, 4 patients affected were immune
suppressed transplanted, completely healed after 8 weeks of treatment. Our study
confirms the efficacy of imiquimod as effective treatment for epithelial NMSC
which leads to complete remission of the most treated lesions without serious side
effects with good compliance of patients.
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Non-invasive therapy of cutaneous neoplasia
F Milla´n, E Quecedo, R Carmena, V Pont, A Alfaro, M Velasco and E. Gimeno
Department of Dermatology, Hospital Arnau de Vilanova, Valencia, Spain
We report two patients with superficial basal cell carcinoma and two patients with
Bowen’s disease treated with 5% imiquimod cream. All the patients refused the
surgical treatment. Superficial basal cell carcinomas were located on the back, and
the Bowen’s diseases were on the frontal region and the right arm. 5% imiquimod
cream was applied at 5 times per week for 6 weeks. Side effects included erythema
and crusting in all patients. Topical 5% imiquimod cream is becoming established
as the first treatment for basal cell carcinoma and Bowen’s disease in those patients
who cannot have or do not wish to have surgery, as in our cases.
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Onset of Actinic Keratosis on Squamous Cell Carcinoma Successfully
Treated with Superficial Radiotherapy
I Carboni, M Papoutsaki, M Teoli, C Cipriani, A Iliopoulou and S Chimenti
Department of Dermatology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Cutaneous squamous cell carcinoma (SCC) accounts for 20% of the dermatological
malignancies. SCC are a heterogeneous group of tumors with many distinctive
characteristics that can affect prognosis or appropriate patients treatment.
Malignant transformation of an actinic keratosis, in squamous cell carcinoma is
estimated at 0.1% per lesion per year. Surgical excision is considered the first
choice treatment, although a number of conditions may modify this approach. We
report a case of a 62 year-old man with evident photoaging of the face presenting
an erythematous-scaled-telangiectasic rectangular lesion (85 cm), localized on
the temporal region, since 10 years and treated occasionally with steroid cream
without results. Histological examination from punch biopsy revealed a SCC
located in the superficial dermis. Because of the extension and the localization of
the lesion, the patient was treated with superficial radiotherapy, using radioactive
beta-emitting isotopes incorporated in a special inert, synthetic and liquid resin,
applied over the lesion for minute to hours depending to the dose. Clinical
evaluation was made monthly. At three months the patient developed little
erythematous areas in the marginal zone of the previous treated lesion. The
histological diagnosis was actinic keratosis associated to moderate displasia. In
conclusion, the phenomenon of field cancerization has often been brought up to
explain the recurrence of SCC and appears to be a critical step in the epithelial
carcinogenesis with important clinical consequences. Diagnosis and treatment of
epithelial cancers should not only be focused on the tumor but also on the field
from which it developed.
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Superficial Brachitherapy with b-Emitting Isotopes for the Treatment of
Basal Cell Carcinoma
AM Carrozzo1, C de Felice1, AF Sedda2, G Rossi2, C Cipriani3 and S Chimenti1
1Dermatology Department, University of Rome ‘‘Tor Vergata’’, Rome, Italy,
2TRIGA Reactor, ENEA-Casaccia, Rome, Italy and 3Nuclear Medicine Division,
S. Eugenio Hospital, Rome, Italy
Surgical excision is the treatment of choice for BCC. New alternative topical
therapies, e.g. imiquimod and tazarotene, are available for the treatment of selected
cases, such as inoperable patients affected by systemic underlying diseases (e.g.
heart failure, pulmonary insufficiency) with lesions located on particular areas (e.g.
ear, nose, eyelids) on which a surgical approach may be very difficult and scars
may be cosmetically not acceptable. Both are used for small, superficial and not
recurrent BCCs, moreover they are not indicated for morphea-form, infiltrative and
nodular lesions. The limited use of this type of therapies is due to high recurrence
rate. We would like to propose a novel therapeutic option that consists in a
superficial radiotherapy, characterized by radioactive beta g-emitting isotopes (P-
32 or Re-188 or Y-90) incorporated in a special inert, synthetic and liquid resin,
which is applied on the lesion with a personalized modality. It may be used for all
types of BCCs, also in the case of large and recurrent forms, with encouraging
results. Superficial brachitherapy with b-emitting isotopes takes place at the nuclear
medicine clinic in a one day treatment that requires a variable time-frame of a few
minutes to a couple of hours in relation to the GY dose calculated. Immediately
after treatment, target lesions show a reactive inflammation that heals in one week.
Complete clinical remission may occur in approximately 3 month.
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Desmoplastic Melanoma
P Piemonte, PP Di Russo, A Ginepri, P Donati, M Costantini and P Frascione
Dermatoloy Division, Regina Elena Institute, Rome, Italy
A 61-year-old man was referred to our department for evaluation of an
asymptomatic cutaneous neoformation of the left fronto-parietal region he had
developed over the last five months. Clinically, the patient presented an indistinct
erythematous area, palpation revealed an indurated freely mobile plaque with
irregular and undefined margins. The lesion had rapidly grown and raised the
diameter of 4 cm. Histologic sections of the surgical resection showed a fibrous-like
proliferation constituted by intersecting fascicles of elongated spindle-shaped cells
that diffusely infiltrated the dermis and the subcutaneous tissue. The cells showed
rare atypical features and there were no mitotic activity. Island of inflammation
were scattered in the surrounding stroma. Immunohistochemical staining revealed
focal reactivity for S-100 protein and negativity for smooth muscle actin and
desmin. The clinical, histological and immunohistological findings were consistent
with the diagnosis of desmoplastic melanoma. Sentinel node mapping was negative
and computed tomography didn’t detect any regional or distant spread.
Desmoplastic melanoma represent a rare variant of melanoma, firstly described
by Conley in 1971, characterized by spindle-shaped cells embedded in an
abundant fibrous stroma, extending into the dermis and the subcutaneous tissue.
Nuclear atypia rate as well as mitotic activity may be greatly variable in the spindle
cell population. In the literature, S-100 is typically positive while HBM-45 is
commonly negative. Desmoplastic melanoma usually occurs in elderly and arise in
photodamaged skin, specially on the head, neck and the upper part of the trunk,
with or without an overlying lentigo maligna-type lesion. Due to its advanced state
at the time of detection, desmoplastic melanoma often show high local recurrence
rate and high tendency for regional and distal metatstasis. Since desmoplastic
melanoma is often amelanotic and may mimic several different conditions such as
scars, neurofibromas, dermatofibromas and basal cell carcinomas, it can be
clinically misdiagnosed.
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Animal Type Melanoma
PP Di Russo, P Piemonte, B Fossati, P Donati and P Frascione
Regina Elena Institute, Dermatology Oncology Division, Rome, Italy
A 17-year-old patient was referred to our department for a nodular blue-black
lesion, 0.5 cm in diameter, located on the lumbar region. Dermoscopic
examination revealed an homogeneous blue-grey pigmentation in absence of
specific features. The lesion was excised and histopathologic examination
demonstrated a nodular, polypoid animal type melanoma, with spindle-cells,
graded as IV Clark’s level, 5.64 mm in Breslow thickness, without ulceration. Wide
re-excision was performed as well as sentinel lymph node sampling which detected
metastatic deposits in the right axillary region. In the excised lymph node, isolated
pigmented cells, staining positively with HMB45 and to MART-1 were observed in
the subcapsular space. Total body TC scan was negative. Animal type melanoma is
a rare variant of melanoma, characterized by fascicles and nests of atypical, heavily
pigmented, epithelioid melanocytes that involve the full thickness of the dermis.
The term derives from the histopathologic similarity of this neoplasm with
melanocytic tumors described in gray horses. Animal type melanoma occurs more
often in adolescent and young adults and usually arise ‘‘de novo’’ in any site of the
body, including genital and mucosal areas, without any predilection. Because only
a few cases of animal type melanoma have been reported, its biological behaviour
is not well defined, data published in the literature seem to show a limited tendency
to spread beyond local lymph nodes and low rates of distant metastasis.
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Bilateral Primary Malignant Melanoma of the Lower Limbs
G Monfrecola, A Baldo, S Lembo and P Maddalena*
Dermatology Department, Federico II University of Naples, Italy and *Surgery
Department, A.S.L. 5, Hospital of Sorrento, Naples, Italy
Malignant Melanoma (MM) is the most common cancer in women aged from 25 to
29. Its incidence is increasing rapidly and has been demonstrated, by
epidemiologic studies, to be related to sun exposure. We report the case of a 43-
year-old lady, referred to our out patient clinic with two bilateral pigmented lesions
on the sural areas, appeared 3 years before, on her lower left leg, first, than, a few
months later, on her lower right leg. When she was referred to our clinic, last
month, the lesions were both irregularly pigmented, the first one, on the left leg,
was nodular, asymmetric, with imprecise margins, measuring 2.5 x 2 cm, the
second lesion on the right leg was flat, patchy pigmented, irregularly shaped,
measuring about 3 cm. She was fair skin and red head (phototype II Fitzpatrick
classification). No other suspicious lesion or palpable lymph node was detected.
She had no personal or family history of relevant medical significance, apart from
frequent sun burns during childhood. Dermoscopic observation of both lesions
revealed atypical pigmented and vascular pattern, multiple blue-grey regression
areas. Histological examination showed malignant melanomas: the left lesion had
3 mm Breslow’s index, Clark level III, stage pT3bNxMx; the lesion on the right leg
had 1.9 mm Breslow’s index, Clark level III, pT2aNxMx . The sentinel lymph nodes
(popliteal cavities) were removed: they were both negative. She was admitted in
our day hospital for a systemic investigation: according to the current procedures, a
low dose Interferon alpha therapy was started.
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Malignant Melanoma Arising in a Pregnant Woman
C Guerriero, B Fossati, I Proietti, E Latella, F Valenzano, I De Martino and PL
Amerio
Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy
For many years, there has been controversy in the medical community regarding
the correlation of female hormonal factors with the outcome of women with
malignant melanoma. Some authors reported that naevi had markedly increased
numbers of estrogen and progesteron-binding cells. The induction of increased
hormonal receptors by pregnancy may be related to the pigmentary changes
observed in female patients in general. Most studies found no difference in overall
survival between pregnant and nonpregnant women with melanoma but there have
been multiple reports that women had thicker tumors and/or a worse prognosis
compared with a group of control women. We describe a case of a caucasian 35
year-old woman that during pregnancy showed dermoscopic changes of a naevus
of abdomen resulting to histological examination melanoma (1 mm sec.
Breslow).The sentinel lymph node was positive. This case confirms that pregnancy
history including age at first birth and parity may play a role in risk of cutaneous
melanoma in women.
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Predictor Features of Sentinel Lymph Node Positivity in Melanomas
41 mm Thick
G Pagnanelli*, R Bono*, MA Pizzichetta#, R Talamini# and I Stanganelli1
*Istituto Dermopatico dell’Immacolata, IRCCS, Rome #Centro di Riferimento
Oncologico, CRO, Aviano and 1Skin Cancer Unit, CPO, Ravenna and Niguarda
Hospital, Milan, Italy
One of the most important aim of the non-invasive methods used to measure
melanoma thickness is to differentiate patients with thin (o1 mm) from thick
(41 mm) tumours and then to perform the sentinel lymph node (SLN) biopsy only
on the latter. Purpose of this study has been to investigate whether specific clinical
and/or dermoscopic features could be ‘‘in vivo’’ predictors of SLN positivity in
41 mm thick melanoma patients. We carried out a blind retrospective study on
508 melanomas observed in 494 patients (221 males and 273 females) between
January 1994 and December 2002. 391 melanomas were o1 mm (77 %) and 117
melanomas 41 mm (23 %). 86 patients (45 males and 41 females) with melanoma
thicker than 1 mm, non-ulcerated and undergone to SLN biopsy were included. The
melanoma palpability shows a statistically significant correlation with SLN
positivity. It is found in 46.2% of SLN positive melanomas and in 18.5% of those
with negative SLN. Moreover patients with palpable melanomas have a
significantly higher risk (OR¼ 3.8; 95% CI: 1.1–13.3; po0.03) for nodal metastasis
than those with flat melanomas. The other clinical features investigated do not
show any significant differences between melanomas with negative and positive
SLN. Dermoscopy failed to recognize statistically significant predictive criteria for
SLN positivity. Specific melanoma features strongly associated with an higher
Breslow thickness such as grey-blue areas or an atypical vascular pattern are not
correlated to SLN positivity. Nevertheless, some clinical and dermoscopic features
show interesting differences, although not statistically significative, between nodal-
negative and nodal-positive melanomas.
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Lentigo Maligna and Tazarotene: Topical Alternative Treatment in
Selected Cases
C de Felice, E Campione, AM Carrozzo, R Saraceno, L Citarella and S Chimenti
Dermatology Department, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Lentigo maligna (LM) is an in situ melanoma located on sun-exposed areas of
middle-aged or elderly patients. Treatment of choice for LM are obviously surgical
excision and Mohs micrographic surgery which provide high cure rate and low
recurrence rate. Other therapeutic options include cryotherapy, curettage and
electrodessication, carbon-dioxide or Q-switched lasers, and radiotherapy. A
variety of medical approaches (e.g. interferon-alpha, azelaic acid, and imiquimod)
have been proposed to treat LM when difficult to excise because of their extension
or location, in selected elderly patients with compromised general conditions. We
report 4 patients, aged 74–85 years (mean age: 81 years), with facial and scalp LM
who experienced complete clinical and histopathological regression after once-
daily topical treatment with tazarotene 0.1% gel for 6–8 months. After a follow-up
period of 3 and 30 months, no recurrence was observed. Patients were submitted to
dermoscopic analysis and histopathologic examination of an incisional biopsy
specimen before treatment, to establish the non-invasive nature of the lesion, and to
confirm the clinical result after treatment. The topical treatment was suggested on
the basis of patients’ poor general condition: chronic obstructive pulmonary
insufficiency, heart failure and Parkinson disease. Moreover, abdomen and lymph
node ultrasonography and thorax radiography were performed every 6 months for
patients’ staging. We believe that tazarotene might be considered as a possible
medical approach in selected patients with lentigo maligna.
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Topical Imiquimod: Efficacy in Intraepithelial Melanoma of the Oral
Mucosa
K Spieth1, AF Kovacs2, R Bug3, M Wolter1, R Kaufmann1 and J Gille1
1Department of Dermatology, 2Department of Oromaxillofacial Plastic Surgery and
3Department of Pathology, University Hospital, Frankfurt am Main, Germany
Oral mucosal melanoma commonly represents a considerable diagnostic and
therapeutic challenge. Surgical excision of the primary tumor and lymphadenect-
omy of affected nodes are the mainstay of mucosal melanoma therapy. Alternatives
to surgical excision include radiotherapy, cryosurgery, and laser therapy. Adjuvant
radiotherapy may improve the chance of local control, yet compelling evidence of
an increased overall survival is lacking. We report on a 67-year-old patient who
presented with a recurrence of an amelanotic oral mucosal melanoma. The primary
tumor was resected by partial maxillectomy. Five months later a local recurrence
was removed surgically. Another 21 months later a second relapse occurred. While
complete surgical excision was again attempted, negative tumor-free margins could
not be achieved despite multiple surgical operations. Histopathology displayed
multifocal intraepithelial spreading of amelanotic tumor cells. As a non-surgical
approach, topical application of the immune response modifier imiquimod three
times a week for 3 months resulted in a histologically confirmed remission.
Maintenance therapy with imiquimod on a twice weekly schedule for another three
months facilitated continuing remission. Thereafter, therapy was ceased with no
evidence of local recurrence or organ metastases noticed after a follow-up of the
patient for more than 15 months now. Next to an erythema of the treated mucosa a
WHO grade 2 leucopenia was the only side effect to be observed. Analogous to the
recently reported efficacy in cutaneous lentigo maligna, the toll-like receptor-7
agonist imiquimod may also constitute an effective palliative treatment option for
selected patients with unresectable intraepithelial mucosal melanoma.
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Selective Electrochemical Tumour Ablation (SECTA): Successful Treat-
ment of Skin Metastases
KC Kaehler, K Jahnke, F Egberts and A Hauschild
Department of Dermatology, University of Kiel, Germany
Selective Electrochemical Tumour Ablation (SECTA) delivers exogenous molecules,
such as chemotherapeutic agents, into cells by enabling a temporary increase in
cell membrane permeability through exposure to pulsed electric fields. Gene-
tronics/Inovio has developed the MedPulsers System, consisting of a pulse
generator and a needle array applicator to perform the SECTA procedure. Currently,
a multi-centre observational study using SECTA combined with intralesional
bleomycin is being conducted to treat cutaneous and subcutaneous foci of cancer
in European centres. We present three cases of skin metastasis treated with SECTA
per this ongoing protocol. A 79 year old female presented with multiple cutaneous
and subcutaneous melanoma metastases of the entire left leg. Besides the
concomitant visceral metastases, the patient’s lesions emitted a strong odour, and
also had a tendency to bleed. We treated 6 lesions with SECTA and excised
concurrently several lesions, which were not eligible for treatment under the
protocol. Biopsies taken 4 weeks after SECTA revealed no viable tumour cells.
Clinically the healing tendency of the SECTA treated lesions was better when
compared to surgery. An 81 year old female with two metastatic melanoma lesions
located in the groin was treated with SECTA and demonstrated a remarkable
tumour shrinkage. Again biopsies revealed no evidence of remaining metastases.
An 83 year old female presented with multiple skin metastases of a malignant
fibrous histiocytoma on the left leg, besides a widespread involvement of visceral
organs. Spontaneous bleeding and a strong odour from the infected lesions
adversely impacted the quality of life of this patient. Concurrent to SECTA, we
excised several large lesions. During the healing process the SECTA-treated lesions
demonstrated a better clinical response in comparison to surgery. In conclusion,
treatment with SECTA combined with bleomycin is an interesting new therapeutic
alternative for achieving local tumour control.
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Primary Cutaneous Diffuse Large B Cell Lymphoma, Leg Type. A Case
Report
A Pasic*, J Rados*, J Lipozencic*, R Ceovic*, I Ilic** and I Radman***
*University Department of Dermatology and Venereology, **University Depart-
ment of Pathology and ***Department of Hematology, University Department of
Medicine, Zagreb University Hospital Center, Zagreb, Croatia
Primary cutaneous B-cell lymphomas (CBCL) are a heterogeneous group of B-cell
lymphoproliferative diseases that are characterized by skin involvement without
detectable extracutaneous disease at the time of diagnosis. In the new World
Health Organization/European Organization for Research and Treatment of Cancer
(WHO-EORTC) classification of cutaneous lymphoma, large B-cell lymphomas are
divided into 3 groups: large B-cell lymphoma, leg type (LBCLLT), follicle center
lymphoma, diffuse type (FCLDT) and large B-cell lymphoma, and other (LBCLO).
We report on a 76-year-old female diagnosed with LBCLLT in November 2005.
Brownish-red plaques and nodules of smooth surface, clustered on her left shoulder
and in the right axilla, with two solitary foci on the abdomen and back, appeared
one month and a half before hospitalization. Extracutaneous manifestations of the
disease were ruled out by clinical examination and laboratory testing. A skin biopsy
specimen showed a dense, diffuse lymphocytic infiltrate in the papillary and
reticular dermis as well as in the subcutis, composed of large dysplastic
lymphocytes with immunoblastic features. Paraffin immunoperoxidase studies
identified the neoplastic cells as B cells, which were CD20, bcl 6, Mum-1 and bcl 2
positive. CD3, CD43 and CD10 stains produced negative results. The patient
received 6 cycles of chemotherapy with cyclophosphamide, doxorubicin,
vincristine and prednisone, which resulted in complete regression of the lesions.
Until now, there has been no relapse of the disease. Close follow up is necessary
because of the higher rate of recurrence and more unfavorable prognosis than in
case of PCFCBL characterized by diffuse, large cell morphology.
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Topical Photodynamic Therapy for Primary Cutaneous B-Cell Lympho-
ma: A Pilot Study
M Mori, R Rossi. P Campolmi, G Bani Assad, N Pimpinelli and T Lotti
Physical Therapy Unit, University of Florence Medical School, Florence, Italy
Photodynamic Therapy (PDT) is a treatment based on the accumulation of a
photosensitizer in the target cells and their selective destruction by irradiation with
visible light. In the past 10 years, several patients with cutaneous T cell lymphoma
have been successfully treated. The use of PDT in cutaneous B cell lymphoma has
not been reported to date. We treated 3 nodular lesion of 3 patients with early
primary cutaneous B cell lymphoma. In two patients we used twenty per cent ALA
dissolved in an oil-water emulsion that was applied topically to the lesion and to
adjacent skin under an occlusive and light-shielding dressing for 3 h. In only 1
patient methylesther of ALA (Metvixs) was applied. The patients were examined
with an interval of 1–2 weeks and, depending on the clinical results, the treatment
was repeated. Four-millimetre punch biopsies were taken before treatment and
after clinical improvement. Clinical evaluation was monthly performed after PDT
with 3–24 months of follow-up. We obtained complete remission in 3/3 after max.
two PDT sessions. The successful use of PDT in indolent CBCL, reported here for
the first time, suggests the possible role of PDT in the treatment of localized, thin
plaques as an alternative to local RT, which remains the treatment of choice.
P30
Treatment of Early Stage Mycosis Fungoides with Topical Bexarotene
M Esposito, A Giunta, A Zangrilli, M Ruzzetti, A Bergamin, M Nicoletti and
A Costanzo
Department of Dermatology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Mycosis fungoides (MF) is the most common cutaneous T cell lymphoma (CTCL).
As long as the disease is confined to the skin, skin-targeted therapies as topical
steroids, photo(chemo)therapy, nitrogen mustard, chlormustine, or radiotherapy are
usually preferred. Despite a number of therapeutic approaches are available,
alternative treatments of MF have been continuously proposed over recent decades.
Particularly, one of the most recent developments in CTCL therapy is the
introduction of topical retinoids. These agents induce their effect by decreasing
proliferation, increasing differentiation and promoting apoptosis as well as acting
on T cell immunity. Bexarotene was the first retinoid X receptor (RXR) to be
approved by the US Food and Drug Administration (FDA) for the treatment of CTCL
and is available for oral or topical administration. Comparing to the first-generation
retinoids, bexarotene presents a more-selective binding pattern. Topical bexarotene
has been evaluated in a phase I–II dose-ranging studies as well as in a placebo-
controlled phase III trial. Complete and partial response were demonstrated in
10–20% and 42–44% of patients, respectively. We treated, as alternative treatment,
3 patients affected by MF (stage IA/IB, IIA) with topical bexarotene 1% gel. Patches
and plaques lesions were treated, every other day, progressively increasing the
frequency of daily application from 1 up to 4 times. The treatment was effective,
well tolerated and patients’ compliance was consistently good. Our results
evidence that topical bexarotene in well-selected cases of MF is a highly effective
treatment, demonstrating rapid and significant clinical response.
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Monochromatic Excimer Light in the Treatment of Early Stage Mycosis
Fungoides: A Two Year Experience
S Nistico`, R Saraceno, A Giunta, M Montaldo, A Iliopoulou and L Bianchi
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy
Treatment of early stage mycosis fungoides (MF) includes various options such as
topical steroids or chemotherapy, UVB phototherapy, and PUVA photochemother-
apy. Efficacy and safety of broadband UVB phototherapy (280–320 nm wavelength)
have been widely reported. 4Recently, several studies demonstrated the efficacy
of narrowband UVB phototherapy (311 nm) and monochromatic excimer light
(M.E.L., 308 nm) in the treatment of early-stage MF. 4Herein we report nine
patients affected by MF treated with onochromatic excimer light. Treatment
sessions were performed at different intervals ranging from 7 to 10 days, gradually
increasing fluencies. No other antineoplastic treatments, both systemic or topical,
were administrated. M.E.L. irradiation was stopped when clinical remission was
achieved. In all cases, histopathological examination confirmed the complete
remission with the absence of residual neoplastic cells. After two-year observation,
eight patients maintained the achieved results being symptoms-free. In one case,
several new MF plaques were observed after 6 week from M.E.L discontinuation. In
conclusion, our 2-year experience suggests that M.E.L. could be considered as a
valid therapeutic option in the treatment of early stage MF with a good efficacy and
safety compared with traditional therapies.
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Unilateral Kaposi’s Sarcoma
D Sa´nchez-Aguilar, O Sua´rez-Amor, J Labandeira-Garcı´a and J Toribio
Department of Dermatology, Clinical University Hospital, Faculty of Medicine,
Santiago de Compostela, Spain
Introduction: Kaposi’s sarcoma (KS) is a rare malignant neoplasm that is thought to
be multicentric in origin but classically presents with acral lesions. KS has been
identified in four different settings: classic KS, African-endemic KS, AIDS-associated
KS and iatrogenic immunosuppressive drug-associated KS.
Case report: We report a 67-year-old Caucasian woman with chronic lymphedema
secondary to right mastectomy 6 years ago, and with end-stage renal disease due to
microscopic polyangeitis who needed treatment with cyclophosphamide, methyl-
prednisolone, and hemodialysis. One month after she started immunosuppressive
therapy she developed SK lesions limited to her right superior limb. No other
cutaneous lesions were noted and investigations failed to reveal any systemic
lesions. Although discontinuation of immunosuppressive therapy did not improve
her skin lesions, these regressed after radiotherapy.
Discussion: KS has been described in a wide spectrum of patients receiving
immunosuppressive drug therapy. Although KS arising in one anatomic area is very
infrequent, it seems that chronic lymphedematous regions are predisposed to
malignancy due to impairment of local immune surveillance. We propose that
immunosuppressive therapy allowed the development of KS at this predisposed
anatomical site.
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Points of View on Kaposi’s Sarcoma: Our Experience
F Buda1, G Svenda1, A De Jeso1, O Bergamo1, P Aragona2, C Buda3 and G
Messina3
1Medical Oncology, ‘‘City of Udine’’ Hospital, Udine, 2Clinical Research
Laboratory & Pathology, S. Vito Hospital, Pordenone, Italy and 3Department of
Surgery and Radiation Oncology, University, Messina, Italy
Text: For our study, 14 cases of Kaposi’s sarcoma which were submitted to our
observation were considered and the histological investigations were effected on
skin biopsies.
Methods: The preparations were divided according to the present views in three
groups: 1) lesions with vascular predominance, 2) lesions with predominance of
spindle cells, 3) mixed lesions, that is, a vascular structure and a spindle cells
structure. On all the histological preparations the technique used was the
immunohistochemical peroxidase anti peroxidase (PAP).
Results: The images obtained on optical microscope of all histological preparations
stained with hematoxylin-eosin confirmed the characteristic polymorphic aspect of
the lesion. It was observed a double vascular and cellular proliferation represented
by the neoformation and by the dilation of blood vessels and from infiltrations,
mainly perivasal, consisting of various types of cells mostly spindle cells gathered in
clumps or sheaves. The vascular cavities, different for number and dimension,
represented some of the vessels of adult type, with continuous endothelial edge,
others were much like a newly formed capillary with discontinuous endothelial.
The vasal cavities in some cases, were clearly predominant and the infiltration
appeared extremely reduced, in others, the infiltration was very abundant so much
so that the lesion appeared almost like a thick tissue, without any vascular new
formations. Therefore, on the microscope the lesions showed up as consisting of
sheaves of spindle cells intersecting with vascular structures in a matrix of collagen
and reticular fibers. Among the spindle cells with pleomorphic nuclei there are red
blood cells and deposits of hemosiderin. Macrophages are present that have
phagocytized the hemosiderin and mononuclear cells of lesions occurred more
recently. The histological preparations we examined showed up positive in the
mmunohistochemical (PAP) research for presence of the VIII factor. The reaction
was clearly visible in the cytoplasm of the endothelial cells that marked the
boundary the vascular spaces. Only in the connective tissue was rarely detected the
presence of isolated cells positive to the reaction PAP, while, usually, large areas of
connective zone were negative.
Conclusion: Like previously stated the histogenesis of Kaposis’s sarcoma is still
being debated. Our immunohistochemical (PAP) research does not confirm what
Nadji and coll. found because the positivity of the factor VIII is limited to the
endothelial spaces with some rare positive element in prevalently stromal forms.
The explanation of this is not easy, even though we think that the positive elements
detected by Nadji and coll. and in part by us, are elements already orientated in the
endothelial direction. Based on these results we obtained, we can assume that
Karposi’s sarcoma, although a vascular tumor, does not have an exclusive
endothelial origin but might derive, in agreement with studies of Niemi and
Mustakalio from a multipotential perivascular mesenchyme capable of a
differentiation into various types of cellular neurofibroblats, fibroblasts, or
endothelial cells.
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Familial Cylindromatosis, a Phenomenon Known as ‘‘Turban Tumors’’ or
‘‘Brooke-Spiegler Syndrome’’
G Kukova1, H Dra¨ger1, J Reifenberger1, U Meyer2, KW Schulte1 and B. Homey1
1Department of Dermatology, Heinrich, Heine University, Duesseldorf, Germany
and 2Department of Facial Plastic Surgery, Heinrich, Heine University, Duessel-
dorf, Germany
Familial cylindromatosis (FC) is a rare autosomal dominantly inherited familial
tumour syndrome characterized by the development of multiple benign adnexal
tumors, including cylindromas, trichoepitheliomas, and spiradenomas. The
cylindromas usually begin to appear in the second or third decades accumulating
in number and increasing slowly in size throughout adult life. The tumours arise
predominantly in hairy areas of the body, with approximately 90% on the head and
neck. Malignant transformation is rare, but well documented. The FC gene
(designated as cylt) with function as a tumor suppressor gene was mapped to
chromosome segment 16q12–q13. Here we present a 57-year-old woman suffered
since early adulthood from multiple tumours arised on the head, neck and trunk.
The increase of tumours on the scalp led throughout the years to the formation of a
confluent mass that became infected and ulcerated. These tumours were up to
25 cm in size, smooth, elastic skin-coloured nodules with superficial telangiecta-
sias. Family history revealed that both brother and mother show similar, but much
less distinct tumours. The diagnosis of cylindromatosis was confirmed by histologic
examination, that revealed lobules of basophilic palisading epithelial cells,
surrounded by thick hyaline membranes and a strikingly sclerotic stroma. The
patient underwent radical surgical excision of the entire forehead and scalp with
secondary wound closure using local skin flaps and split-thickness skin grafts.
Taken together, we present here a patient with massive cylindromas located on the
head covering the entire scalp, resulting in so called ‘‘turban tumors’’, that
represents a big surgical challenge and requires an interdisciplinary approach.
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Brooke-Spiegler Syndrome: Variable Phenotypes in a Four-Generation
Family
T Surrenti1,2, N Haas2, J Frank3, S Schweiger2, K Peris1 and W Sterry2
1Departments of Dermatology, University of L’Aquila, L’Aquila, Italy, 2University
Hospital ‘‘Charite´’’, Berlin, Germany and 3Department of Dermatology, University
Hospital Maastricht, Maastricht, The Netherlands
Brooke-Spiegler syndrome (BSS) is a rare autosomal dominant disorder that is
clinically characterized by multiple trichoepitheliomas and cylindromas and
eventually other adnexal skin tumors. We describe a four-generation family with
BSS and a clear autosomal-dominant inheritance and an imposing variability of
phenotypes. The proband is a 12-year-old boy of German origin who developed
multiple nodular lesions on the scalp with histopathologic features of both
spiradenoma and cylindroma in the same tissue specimen. The patient’s father and
aunt presented each with both multiple cylindromas on the scalp and
trichoepitheliomas on the face. In addition, an uncle was affected by multiple
trichoepitheliomas on the nasolabial folds, and the grandmother and great-
grandfather had multiple papules in the face and nodules on the scalp. Mutations in
the CYLD1 gene, located at 16q12–13, have been recently found to underlie the
development of BSS in most families. In a molecular genetics approach using DNA
from three members of our family (proband, the patient’s father and aunt) we could
exclude a deletion of G2253 in the CYLD1 gene, which had previously been
identified in a large German pedigree and thus could exclude a founder effect in
German families with BSS. The simultaneous occurrence of different phenotypes of
BSS, as seen in our family, confirms the clinical and histopathological variability of
BSS, and corroborates the pathogenetic impact of modifying genes and/or
environmental factors in the expression of the BSS phenotype.
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Muir-Torre Syndrome with Fatal Outcome
E Campione*, A Orlandi1, A Mazzotta*, L Bianchi*, M Esposito*, G Mio* and
S Chimenti*
*Department of Dermatology and 1Department of Pathology, University of Rome
‘‘Tor Vergata’’, Rome, Italy
Muir-Torre syndrome (MTS) is an autosomal dominant genodermatosis character-
ized by the association of sebaceous gland tumour, one or multiple keratoacantho-
mas and internal malignancies. MTS is a phenotypic variant of hereditary non-
polyposis colorectal cancer (HNPCC). MTS and HNPCC are caused by germline
mutations in the DNA mismatch repair (MMR) genes MSH2 or MLH1. Skin cancer
and internal malignancies of MTS patients show high microsatellite instability (MSI-
H). We describe a case of a 40-year-old female referring the onset of 10 rapidly
growing nodular, asymptomatic scalp lesions, histologically diagnosed as sebac-
eous carcinomas. Her past medical history did not reveal underlying diseases, but
her family history evidenced a first degree relative affected by colon cancer. The
aggressive eruption of the sebaceous carcinomas and the positive family history for
internal neoplasm, led us to request a genetic counselling confirming the diagnosis
of MTS. MSI and immunohistochemical examination of MSH2 and MLH1 protein
in patient’s sebaceous carcinomas were performed. Gastroscopy and colonscopy
gave negative results for colon cancers, whereas TC scan evidenced a solid mass at
the posterior part of the mediastinum and multiple nodular lesions in pulmonary
and pleuric tissues. The histopathological exam of the nodular lesion confirmed the
diagnosis of metastasis from sebaceous carcinoma. The patient died 1 year after the
first diagnosis. Besides the rare occurrence of MTS, we underline the severe
aggressive behaviour of the case presented and the usefulness of the immunohis-
tochemical testing as a reliable screening method with high predictive value for the
diagnosis of MMR in MTS patients.
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Keratosis Punctata Palmoplantaris and Malignancies: Case Report
S Nistico`, R Saraceno, A Costanzo, I Carboni and S Chimenti
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy
Keratosis punctata palmoplantaris (KPPP, Buschke-Fischer-Brauer syndrome or
keratoma disseminatum) is a rare genodermatosis with an autosomal-dominant
pattern of inheritance, characterized by disseminated cup-shaped horny papules
with central depression containing keratotic plugs. The disease is circumscribed on
the palms and soles and associated abnormalities, such as colon adenocarcinomas,
basal cell carcinomas are usual and have been reported previously thus many
authors refer to this syndrome as paraneoplastic. We report the case of a 61-year-
old man who presented with a long history of multiple symptomatic hyperkeratotic
papules on the palms and soles; in addition, association with various anomalies
including malignancies such as multiple poliposis of the colon were reported.
Family pedigree was analyzed and histological analysis was performed confirming
diagnosis. Topical retinoid Tazarotene (0.1% gel) and Urea (50% cream) were
prescribed with an improvement of cutaneous symptoms after a 2 month
observation. In our opinion, genetic studies could reveal whether cutaneous
phenotypes such as punctate palmoplantar keratoderma with no clinical evidence
of malignancies could be associated with increased cancer susceptibility.
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Our Experience with Metastatic Carcinomas of the Skin: an Eleven-Year
Retrospective Study
A Pasic, J Lipozencic, R Ceovic, I Dobric, J Rados and D Ledic Drvar
University Department of Dermatology and Venereology, Zagreb University
Hospital Center, Zagreb, Croatia
Cutaneous metastasis may represent the first sign of tumor spread from its primary
organ, or the first sign of a cured tumor recurrence. According to recent literature,
between 3% and 10% of cancer patients have cutaneous metastases. We report on
22 patients with histologically verified diagnosis of metastatic skin disease recorded
at our Department during an 11-year period (1994–2004). There were five men and
17 women, age range 46–84 in men and 42–88 in women. In men, the primary
tumor site was lung in 2 cases, whereas in the remaining three cases primary tumor
was unknown at the time of histologic diagnosis. In women, breast cancer was by
far the most common cause of skin metastases (n¼ 12), in three cases the primary
site was unknown, whereas malignant melanoma and primary gynecologic tumor
were found in one case each. As for clinical manifestations, metastases of lung
cancer appeared as noduli located on the abdomen, back and extremities.
Metastases of breast cancer appeared as carcinoma en cuirasse, carcinoma
erysipelatodes, cicatricial alopecia and different types of nodule and papules. It is
of great importance to diagnose metastatic cutaneous carcinomas as early as
possible in order to provide for appropriate treatment of primary cancer, which is
very often modified when skin metastases are found.
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Inflammatory Cutaneous Metastasis of Bladder Carcinoma
A Zangrilli, L Sarmati*, A Orlandi**, L Citarella, L Bianchi and S Chimenti
Departments of Dermatology, *Internal Medicine and **Pathology, University of
Rome Tor Vergata, Rome, Italy
Urinary bladder carcinoma is the fourth most common cancer in men and the ninth
in women; cutaneous metastasis have been reported in 2%–8% of cases. We report
a 56-year-old woman who was examined for an erythematous plaque with an
erysipelas-like appearance located on the inguinal area and both legs. The patient
had undergone surgery for a bladder adenocarcinoma 2 years earlier and since that
time had been treated with systemic chemotherapy. One year later the patient was
hospitalized at the department of Internal Medicine for macroscopic hematuria and
was referred to our clinic for an erythematous plaque that had appeared two
months earlier. Physical examination showed an asymptomatic, indurated, warm,
erythematous plaque with an erysipelas-like appearance, located on the inguinal
area and both legs. Numerous erythematous papules overlying the plaque lesion
were also present. Histopathologic examination of a skin biopsy specimen showed
a dense, diffuse infiltrate of neoplastic cells located in the upper dermis to the
subcutaneous tissue, with sparing of the epidermis. Neoplastic cells, arranged both
in glandular-like structures and in indian file, exhibited abundant cytoplasm and
nuclear anaplasia. Immunohistochemistry showed positivity of neoplastic cells for
pan-cytokeratin (CK), CK 5, CK 7, borderline positivity for CEA, and negativity for
vimentin and PAP. Staging work-up (CT total body and bone scintigraphy) revealed
liver, lung and bone metastases. The patient died 4 months later of widespread
metastatic disease. In the case presented here, unusual clinical aspects of
cutaneous metastasis from bladder adenocarcinoma, included the erysipelas-like
appearance and the uncommon location of the lower extremities, are described.
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A Brownish Macule on the Tip of the Nose
D Calista, L Riccioni* and L Cerbone**
Department of Dermatology, ‘‘M. Bufalini’’ Hospital, Cesena, Italy, *Pathology
Unit, ‘‘M. Bufalini’’ Hospital, Cesena, Italy and **Centro Plinio, Ercolano, Napoli
A 70-year-old man presented complaining of the radial growth and darkening of a
pigmented lesion on the right aspect of the tip of his nose. The patient was a builder
and had been chronically exposed to solar UV radiation all his life. On clinical
examination, we found the lesion to be a round, symmetrical macule, 10 9 mm in
diameter, with regular borders and light brown in colour. A radical excision was
performed and histopathologic examination showed the lesion to be composed of
in-situ melanoma, basal cell carcinoma, compound melanocytic nevus and actinic
keratosis. The coexistence of different tumours in the same cutaneous specimen is a
well-documented, but rare, event. The different neoplasms may originate from a
single or multiple cluster of cells of epithelial, melanocytic or mesenchimal origin.
The pathogenesis of cutaneous collision tumours remains speculative. Most authors
believe such an event is merely a coincidence, mainly related to exposure to
environmental factors such as ultraviolet radiation. In some instances, the
concurrence of more than one lesion could be part of a genetic syndrome or
hamartomatous structure. In other cases, authors have theorized that one neoplasm
might produce tissue changes in the surrounding epithelial or stromal area able to
induce a second tumour.
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Merkel Cell Carcinoma in a Heart Transplant Recipient - A Rare but
Highly Aggressive Malignancy
M Ulrich, C Ulrich, W Sterry and E Stockfleth
Skin Cancer Center Charite´, Department of Dermatology, University of Berlin,
Germany
Background: Merkel cell carcinoma (MCC) is a rare malignancy which seems to
have an increased incidence in transplant patients.
Case Presentation: We report a case of a 61-year-old patient who developed a MCC
on his right forearm 7 years after heart transplantation. At time of diagnosis the
diameter of the lesion measured 2 cm, the axillary sentinel lymph node biopsy was
positive. The patient received an immunosuppressive regimen with Cyclosporine
and Azathioprine. The primary lesion was excised with a 1 cm safety margin.
Already 2 months after initial diagnosis the patient developed a satellite metastasis
and during the following months more satellites occurred. Treatment consisted of
wide local excision, lymph node dissection, hyperthermic limb perfusion and
radiotherapy with a total dosage of 40 Gy. Moreover the Azathioprine was
substituted by Everolimus, an immunosuppressant known to be negatively
associated with skin malignancies post-transplantation. 4 subcutaneous metastasis
developing 6 months later in his right axilla were excised. Subsequently,
chemotherapy with liposomal doxorubicin was started, but had to be discontinued
after 2 cycles due to severe side effects. Chemotherapy was switched to 5-FU, but
the disease progressed with new metastasis to the kidney, spleen, lymph node and
orbit. The patient died 18 months after the primary diagnosis.
Conclusion: MCC is a highly aggressive skin tumor which has a worse prognosis in
immunosuppressed patients. Regular dermatologic aftercare is therefore of special
importance for early detection and treatment initiation in this patient group.
Furthermore switch of immunosuppression should be considered.
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Orbital Xanthogranuloma Associated with Adult-Onset Asthma
FS Delli, M Zioga, I Mandekou-Lefaki and G Chaidemenos
State Hospital for Skin and Venereal Diseases, Thessaloniki, Greece
We report a case of adult orbital xanthogranuloma associated with adult-onset
asthma in a 45-year-old man. The patient presented bilateral, indurated, yellow
eyelid lesions. Adult-onset asthma was diagnosed three years before the
appearance of the rush. Incisional biopsy of the eyelid lesions demonstrated a
diffuse histiocytic infiltrate of the orbit and Touton giant cells without evidence of
necrobiosis. The absence of Birbeck granules within the histiocytic elements of the
tumor, indicating that the cell of origin is a non-Langerhans histiocyte, was
documented with electron microscopy study. Systemic evaluation failed to show
evidence of bone lesions or paraproteinemia. Many systemic treatments were
proposed. Improvement was achieved with high-dose oral corticosteroids. When
patients present with atypical indurated yellow eyelid lesions, a biopsy should be
considered. If Touton giant cells are present, a systemic evaluation should be
performed to rule out both Erdheim-Chester disease and necrobiotic xanthogranu-
loma. If no systemic findings other than adult-onset asthma are present, the rare
entity of adult orbital xanthogranuloma should be considered. Effective treatment
usually includes surgical excision combined with oral corticosteroids.
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Cutaneous Multifocal Angiosarcoma Localised on the Left Lower Arm
D Bachter and K Grunow
Department of Dermatology, Venerology and Allergology, Cottbus, Germany
We present a 66-year-old male patient in good general condition developing
asymptomatic skin lesions on the left lower arm for the last two months. On
examination, we found more than 50 erythematous maculae and papules in
diameter up to 3 mm. Additionally, two livid nodes 9 mm in size could be seen.
Skin biopsies showed an angiosarcoma. In regard to the localised appearance of the
tumor on the extremity, we decided to perform an isolated hyperthermal limb
perfusion of the left arm using melphalan and tumor necrosis factor alpha, followed
by radiation with an overall dose of 40 Gy. During the follow-up period the skin
lesions persisted, but repeated skin biopsies revealed no signs of the former
diagnosed angiosarcoma.
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Malignant Peripheral Nerve Sheath Tumor versus Metastatic Malignant
Melanoma
U Scheller1 and D Bachter2
1Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrich-
shain, Berlin, Germany and 2Department of Dermatology, Venerology and
Allergology, Cottbus, Germany
A 44-year-old woman in good general condition with a rapid growing skin tumor
on the lower abdomen was sent to our hospital. Three weeks ago a node has been
incompletely removed on the same site. Its histological examination suspected a
metastasis of a malignant melanoma. As there was no history of malignancy,
detailed overall work up was inconspicuous and clinical impression believed of a
primary cutaneous tumor, we decided to remove it surgically with a safety margin
of 3 cm to all sides and to perform a gamma-guided sentinel lymphonodectomy.
Histological findings showed a well defined non capsulated tumor consisting of
pleomorphic spindle shaped cells arranged in a fibrosarcoma-like pattern with no
epidermal involvement. Many mitotic figures were seen. Immunohisto-chemical
stainings were positive for S-100, NSE and NK1-C3, negative for Melan A and HMB
45. The sentinel nodes, located in both groins, revealed no tumor cells.
Summarizing we diagnosed a malignant peripheral nerve sheath tumor. During
the 4-year follow-up period neither metastases nor recurrences occurred.
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Cutaneous Angiomatosis in Familiar Cerebral Cavernous Malformations
E Campione*, L Bianchi*, A Terrinoniy, C Mordenti*, A Orlandi1, M Talamonti* and
S Chimenti*
*Department of Dermatology, University of Rome "Tor Vergata", yIDI, IRCSS
Biochemistry Laboratory, c/o Department of Experimental Medicine, of Rome ‘‘Tor
Vergata’’ Rome and 1Department of Pathology, University of Rome ‘‘Tor Vergata’’
Cerebral cavernous malformation (CCM) is an autosomal dominant disease caused
by mutation of CCM1 gene, Krev interaction trapped-1 (KRIT1) on chromosome
7q21-q22. Other CCM loci were documented in chromosome 7p15-p13 (CCM2)
and 3q25.2-q27(CCM3). CCM is a life-time risk disorder, because of the possible
onset of haemorrhages, strokes, seizures and focal neurological deficits. The
magnetic resonance imaging (MRI) is the best diagnostic modality. The CCM
patients and/or their first degree relatives may develop multiple cutaneous vascular
malformations. In this light, the dermatologist may contribute to a pre-symptomatic
diagnosis of CCM, leading the patient to MRI investigations, genetic counselling
and close monitoring to establish prompt treatment if symptoms will occur. We
describe two unrelated cases referred to us for multiple asymptomatic cutaneous
blue nodular lesions localized on the trunk, upper and lower extremities which
arose as lilaceous capillary-venous subsequently growing as blue nevus-like
nodules. The histology confirmed the diagnosis of multiple cutaneous angioma-
tosis. In the first patient, a 56 year-old female, the cutaneous vascular lesions, since
5 years, and a diagnosis of not specific myelitis, were coexistent. Furthermore, her
daughter had to surgically removed one cerebral cavernoma. We proposed a
cerebral MRI for our patient which documented CCM. The second patient, a 43
year-old female suffering from frequent headache, was similarly affected by
cutaneous angiomatosis since 2 years. The cerebral MRI proposed for her displayed
multiple CCM. Genetic analysis on KRIT1 on chromosome 7q21-q22 (CCM1),
7p15-p13 (CCM2) and 3q25.2-q27(CCM3) will be presented and discussed.
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APACHE Syndrome: Acral Pseudolymphomatous Angiokeratoma
E Di Lella, P Piemonte, P Donati, PP Di Russo and P Frascione
Regina Elena Institute, Dermatology Oncology Division, Rome, Italy
The APACHE syndrome is characterized by red nodules in the acral region
resembling clinically angiokeratomas and showing histopathologically a massive
lymphohistiocytic infiltrate beneath the epidermis. The syndrome was initially
thought to be a vascular naevus, but subsequent reports suggested that it represents
a pseudolymphoma rather than angiokeratoma in accordance with its histopato-
logic and immunohistochemical features. We’ll describe a case of a 35 years old
boy presented with 30 years history of asymptomatic red nodules and plaques on
the right forearm, measuring up to 15 mm in diameter. Excisional biopsy revealed
well demarcated, dense infiltrate immediately beneath the epidermis and
perivascular infiltrates in the mid- and lower dermis. The infiltrate was composed
mainly of equal numbers of CD4þ and CD8þ T cells and equal numbers of B
cells. The overlying epidermis showed focal parakeratosis, atrophy and liquefaction
degeneration of the basal cells with exocitosis of lymphocytes and plasma cells.
PCR amplification of rearranged immunoglobulin heavy chain genes or T cell
receptor g genes showed no evidence of clonality, suggesting that these infiltrates
were polyclonal both for B and T cells. The histopathologic and immunohisto-
chemical findings in our patient were consistent with a diagnosis of APACHE.
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Xeroderma Pigmentosum: Description of Two Familiar Cases Observed
in the Italian Dermatological Hospital (IDH) of Quiha`, Ethiopia
V Padovese, C Catricala`1, R De Vita2, M Carducci3, P Grammatico4, S Trincone, R
Calcaterra and A Morrone
Department of Preventive Medicine for Migration, Tourism and Tropical
Dermatology. San Gallicano Institute, Rome, Italy, 1Department of Dermatology/
Oncology, San Gallicano Institute, Rome, Italy, 2Department of Plastic Surgery.
Regina Elena Institutre, Rome, Italy, 3Department of Allergology and Inflammatory
Dermatology, San Gallicano Institute, Rome, Italy and 4Medical Genetics, La
Sapienza University, S. Camillo-Forlanini Hospital, Rome, Italy
Xeroderma Pigmentosum is a hereditary disorder affecting the mechanisms that
regulate DNA repair, and can cause an increase in the death of cells or a delay in
their replication and it can also facilitate a neoplastic transformation of the cells.
This genodermatosis is a rare autosomal recessive disease and is characterized by
severe photosensitivity and especially malignant and precocious tumors (e.g.
malignant melanoma, brain tumors, testicular tumors, pulmonary cancer, or
appearance of leukemia). Inbreeding increases the likelihood of a person being
born with this disease – it normally manifests itself in about 1 out of every 200,000
live births – there is an increased prevalence of Xeroderma Pigmentosum in cultures
that do not discourage this type of reproductive behavior, in Tunisia, for example, 1
out 10,000 people have this disease. Clinically, the disorder manifests itself in skin,
eye, and central nervous system diseases. Moreover, Xeroderma Pigmentosum is
particularly correlated with precocious skin tumors (this is especially true in areas
like Ethiopia, where residents are subject to high levels of sun exposure). This is the
case of two young Ethiopian siblings, ASM a 5 year-old boy, and NSM a 9 year-old
girl, affected by Xeroderma Pigmentosum. Both came to Italian Dermatological
Hospital (IDH) because of lentigo solar and solar keratosis on their faces, hands,
necks, and upper torso (that is, those parts of the body most exposed to the sun).
ASM had a squamous cell carcinoma of the nose. NSM, who is also completely
blind, had a nodular lesion on her scalp in the area of her left parietal. The lesion,
which turned out to be nodular melanoma, was about 8 cm in diameter with a soft
consistency and frequent bleeding. Both of the children were transferred to a
hospital in Italy, where they received treatment, genetic examination and follow-up
care.
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Telediagnosis and Face-To-Face Diagnosis Reliability for ‘‘Pink’’ Lesions
A Balato, G Fabbrocini, O Rescigno, M Scalvenzi, B Brunetti* and F Ayala
Department of Dermatology, Federico II University of Naples, Italy and *Santa
Maria della Speranza Hospital, Salerno, Italy
Telemedicine is a healthcare practice, which utilizes interactivity between audio,
visualization and data communication. Recently, teledermatology has roused much
interest. It can be applied in two ways: in real time, utilizing videoconferencing
equipment, or by store-and-forward methods, whenever transmitted digital images
or pictures are memorized as patient’s clinical background. Dermoscopy enlarges
its points of interest on clinical morphology of skin lesions. Digital analysis,
computer-aided diagnosis and teledermoscopy are new systems that would change
the current management of general skin cancers, and particularly melanoma. The
purpose of this study is to determine the diagnostic reliability, according to inter-
observer agreement between: clinical and dermoscopic diagnosis of poorly
pigmented lesions; face-to-face diagnosis and the telediagnosis. 44 lesions were
examined by two different dermatologists with good and similar experience in
dermoscopy. A store-and-forward teledermatological system, based on clinical and
dermoscopic images, was performed by two skilled dermatologists. The agreement
was investigated using Cohen’s K statistics. According to literature, our results show
that dermoscopic diagnosis improves the clinical aspect and it has a better
concordance with histological diagnosis in face-to-face consultations, unlike results
obtained by telediagnosis. These showed a high concordance between clinical and
dermoscopic diagnosis, both generally presenting a lower concordance, compared
to histological diagnosis. These preliminary results underline that teleconsultation
of dermoscopic images, about pigmented skin lesions, characterized by ‘‘pink’’
color, doesn’t provide a similar degree of diagnostic accuracy as otherwise in face-
to-face diagnosis, perhaps for the absence of typical criterias. Atypical skin lesions
teleconsultation is characterized by the absence of typical dermoscopic pattern and
it can decrease the accuracy of the diagnosis.
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Dermoscopy Experts vs Dermoscopy Non-Experts: A Comparison
Between Face-to-Face Diagnosis and Telediagnosis for the Observation
of ‘‘Pink’’ Lesions
G Fabbrocini, A Balato, O Rescigno, F Ayala. Panelists: M Nino, V Dente, B
Brunetti*, A Baldo, EM Procaccini** and S Beatrice*w
Department of Dermatology, University Federico II, Naples, Italy, *Santa Maria
della Speranza Hospital, Salerno, Italy and **Dermatologia ambulatoriale, ASL
Napoli 1, Naples, Italy
Teledermoscopy holds a great potential regarding the revolutionizing delivery of
dermatology services, providing distant services to areas allowing primary
physician cares to excellent dermatological centres to refer to patients at a
distance. The high melanoma mortality rate is the greatest challenge that
dermatology is facing today. Early melanoma diagnosis is the most important tool
to decrease the mortality rate of skin tumours. 4Dermatological dermoscopy, also
called epiluminescence microscopy (ELM) is a non-invasive method that has
provoked a great revolution for the early diagnosis of pigmented skin lesions.
Teledermoscopy uses telecommunication technologies to transfer images of skin
lesions via Internet, for teleconsultation. This system is a common new tool that
allows second experts’ opinions for the management of atypical lesions, also for
dermoscopic observation. The purpose of our study is to determine the agreement
between 6 dermatologists divided in two groups of 3 each: one group with good
experience in dermoscopy and one group with low experience, comparing a face-
to-face diagnosis versus telediagnosis of clinical and dermoscopic observation of
‘‘pink’’ lesions. 4Our results showed that dermoscopy improves clinical diagnosis
both by skilled and non-expert observers. This improvement was unexpectedly
slightly higher for low experience participants in dermoscopy. Our preliminary
results evidenced two important tools for telediagnosis of low pigmented ‘‘pink’’
skin lesions, without typical dermoscopic criteria: a) a high experience in
dermoscopy is not always associated to diagnosis improvement, in absence of
characteristic patterns; b) telediagnosis, compared to face-to-face diagnosis, has a
lot of limits for these atypical lesions, defined as ‘‘pink’’. It is necessary to define a
new diagnostic algorithm for skin lesions clinically defined as ‘‘pink’’.
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Dermoscopic Changes of Spitz/Reed Nevus in Childhood
T Micantonio, D Piccolo, MC Fargnoli and K Peris
Department of Dermatology, University of L’Aquila, L’Aquila, Italy
Spitz/Reed nevus is a benign melanocytic neoplasm that simulate melanoma both
clinically and histopathologically. Dermoscopic analysis has proven useful to
differentiate Spitz/Reed nevus from other benign or malignant lesions, improving
the diagnostic accuracy of such nevus from 56% to 93%. The most frequent and
well characterized dermoscopic aspects of Spitz/Reed nevus include the starburst,
globular, homogeneous and atypical patterns. Recently, other dermoscopic features
of Spitz/Reed nevus have been described such as the hypopigmented and the
reticular patterns. In addition, some authors demonstrated that in time remarkable
dermoscopic changes may be observed in Spitz/Reed nevi occurring in childhood.
We report the dermoscopic features of 15 Spitz/Reed nevi of 15 patients (6 males
and 9 females; mean age: 8 years) which have been followed-up for 6–48 months
(mean: 27 months). In 6 of 15 cases we observed changes from globular to starburst
pattern and after 6–18 months (mean: 12 months) to an homogeneous pattern. Four
of 15 cases initially showed a globular pattern and then a starburst pattern followed
by a reticular pattern after 4–18 months (mean: 11 months). In 2 of 15 Spitz/Reed
nevi we observed evolution from an hypopigmented to an atypical pattern after 6
and 8 months, respectively. Increased size of the lesion in the absence of any
dermoscopic changes were detected in 3 of 15 lesions. Our results suggest that the
different dermoscopic patterns observed in Spitz/Reed nevi may represent
sequential steps of the biological evolution of the lesion rather than different
clinico-pathological entities.
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Deep Pigmented Seborrheic Keratosis- Clinically and Dermoscopically
Mimicking a Regressing Melanoma
Z Pastar, J Lipozencic1 and J Rados1
Health Department, Ministry of Defence, Croatia and 1Department of Dermatology
and Venereology, Zagreb University Hospital Center, Salata 4, Zagreb, Croatia
We report a 76-year-old man with a history of numerous seborrheic keratoses and
basal cell carcinoma, who presented with a pigmented suspicious lesion on the
right part of abdomen without known history of duration. It was asymmetric,
irregularly demarcated, irregularly pigmented with light and dark brown areas
peripherally and white-bluish areas centrally, slightly elevated in some parts,
measuring 1.3x1.5 cm. Dermoscopically, at the central and at the left peripheral
part of the lesion, a regressive area with brown-bluish peppering effect was seen
while at the lateral parts areas of seborrheic keratosis with numerous milia-like
cysts on a background of brown diffuse pigmentation were seen. As confident
exclusion of regressing melanoma could not be made, the excision was done.
Histopathologic examination revealed deep pigmented seborrheic keratosis and
changes in the central part were consistent with regressive changes seen in lichen
planus-like keratosis.
P52
A Clinical-Dermoscopic Study on 48 Cases of Melanoma with a
Diameter o 6 mm
A Ferrari, P Buccini, G Mariani, V Silipo, A Amantea and C Catricala`
Clinical-Sperimental Department of Oncologic Dermatology, Santa Maria and San
Gallicano, IRCCS, Rome, Italy
We performed a retrospective clinical-dermoscopic study of the images of 506
histopathologically proven melanomas collected at the melanoma Unit of San
Gallicano Dermatological Institute, between January 2002 and December 2004.
All lesions with a diameter o 6 mm that showed at least two of the ABCE clinical
criteria were evaluated by dermoscopy. Forty-eight of 506 melanomas were
retrieved. Forty-two patients were included (32 women and 10 men, mean age:
36.6). Individual lesions were located on the lower limbs (36), trunk (8) and upper
limbs (4). The diameter of the lesions varied from 3.4 mm to 5.9 mm (mean:
4.9 mm). Histopathology showed that 34/48 (70.8%) lesions were melanoma in situ
and 14/48 (29.2%) were invasive superficial spreading melanomas. The Breslow
thickness of invasive melanomas ranged from 0.3 mm to 0.9 (mean: 0.53 mm).The
most common dermoscopic findings were: i) irregular dots/globules (58.3%), ii)
atypical pigment network (48%) and iii) irregular streaks (43.7%). A blue-whitish
veil was observed in 4/48 (8.3%) melanomas, whereas regular streaks were found
in 3/48 (6.2%) lesions. The presence of at least one melanoma-specific criteria,
such as atypical pigment network, irregular streaks or blue-whitish veil was found
in 30/48 (62.5%) melanomas. In 7/48 (14.6%) lesions one clinical criterion was
associated with changes in shape, size and/or color of the lesion during the 6-
month follow-up. Digital dermoscopic follow-up showed an increase in number of
dots/globules and/or the thickening of the pigment network and/or neovasculariza-
tion. Dermoscopy can represent a useful tool to differentiate benign from malignant
small melanocytic lesions.
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Dermoscopic Features of Facial Pigmented Actinic Keratosis
T Micantonio, D Piccolo, MC Fargnoli, I Zalaudek*1, G Argenziano1 and K Peris
Department of Dermatology, University of L’Aquila, L’Aquila, Italy, *Department of
Dermatology, University of Graz, Graz, Austria and 1Department of Dermatology,
University of Naples, Naples, Italy
Actinic keratosis (AK), historically regarded as a premalignant lesion, is now
considered by some authors to be an intraepidermal squamous cell carcinoma.
Pigmented AK is clinically characterized by a dark-brown to gray-bluish coloration
and a smooth, verrucous or slightly scaly surface. At clinical examination,
pigmented AK may be difficult to distinguish fromother pigmented lesions such as
solar lentigo, lentigo maligna, seborrheic keratosis, lichenoid keratosis and
pigmented basal cell carcinoma. Dermoscopic analysis is useful to differentiate
benign from malignant pigmented skin lesions. However, specific dermoscopic
criteria for pigmented AK have been not well defined so far. We investigated the
dermoscopic patterns of 35 histologically proven pigmented AK located on the
face. The study population consisted of 19 males and 16 females with an age
ranging from 63 to 89 years (mean: 76 years). The following dermoscopic features,
either alone or combined, were observed: i) multiple gray to brown dots and
globules around hair follicles (88.6%); ii) brown to gray typical pseudonetwork
(86.0%); iii) annular granular-like pattern (17.1%); iv) dark-brown to gray-bluish
irregular streaks (11.0%). In 3 cases we were mislead by the presence of
asymmetric pigmented follicles, annular-granular pattern and rhomboidal struc-
tures, which are dermoscopic findings characteristics of lentigo maligna. In
conclusion, the knowledge of specific dermoscopic features of pigmented AK is
useful for their characterization and to differentiate pigmented AK from both
melanocytic and non-melanocytic skin lesions. Surgical excision is demanded
when clinical and dermoscopic diagnosis is difficult or almost impossible.
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Targetoid Hemosiderotic Hemangioma: A Thrombosed Hemangioma
with a Slow and Quite Complete Clinical and Dermoscopic Regression
P Piemonte, A Ginebri, J Hagman, PP Di Russo, M Carrera, P Donati and P
Frascione
Dermatology Division, Regina Elena Institute, Rome, Italy
A 18-year-old patient presented with a symptomless targetoid maculo-papular
lesion, 1.5 cm in diameter, located on the medial region of the right thigh; the
lesion consisted in a violaceous papule with a focal black area, surrounded by a
thin flesh-coloured area and by an ecchymotic peripheral ring. The patient reported
that the lesion was a pre-existing hemangioma which had evolved over the last few
days. Dermoscopic examination showed an homogeneous pattern with red lagoons
in the papular part of the lesion with a well demarcated black macule consistent
with a thrombo-hemorrhagic phenomenon; the ecchymotic halo appeared as a
violaceous macular ring with an homogeneous pattern. The diagnosis of targetoid
hemangioma was made on the base of the anamnestic, clinical and dermoscopic
data and a short term follow-up was decided. Three months later, the lesion was
clinically quite completely cleared; dermoscopically, there was a diffuse light
brown pigmentation in the absence of distinctive features. Targetoid hemosiderotic
hemangioma, also known as hobnail hemangioma is a benign, solitary vascular
tumor, firstly described by Santa Cruz and Aronberg in 1988, which occurs more
frequently in young subjects, affecting the trunk and the extremities. It is clinically
characterized by a brown to violaceous papule surrounded by a pale rim and an
outer ecchymotic halo. This case report is characterized by the unusual
spontaneous regression of the lesion which was only appreciable as a post-
inflammatory hyperpigmentation. Furthermore, this case underline how dermo-
scopy is helpful and reliable for the diagnosis of targetoid hemosiderotic
hemangioma and that regular follow up allow to avoid useless surgical excisions.
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Dermoscopic Follow-Up of Acral Melanocitic Nevi
D Altamura1 MC Fargnoli1 D Piccolo1,F Sera2 and K Peris1
1Department of Dermatology, University of L’Aquila, L’Aquila, Italy and
2Epidemiology Department ASL RM/E, Rome, Italy
In this study, we retrospectively analyzed the changes over time of the dermoscopic
patterns observed in 264 melanocytic nevi located on acral volar skin. The
dermoscopic follow-up of the lesions varied from 6 to 90 months (mean: 27.4
months). The baseline images showed the following benign patterns: parallel
furrow (24.62%), globular (15.53%) and double-line (8.33%) variants of the pattern
furrow, latticelike (15.91%), fibrillar (11.36%), nontypical (10.23%), homogeneous
(4.55%), reticular (2.65%), transition (3.03%), globular (3.41%) and starburst
pattern (0.38%). Follow-up at 6 and 12 months was available for 123 lesions, while
the dermoscopic images of 63 nevi were evaluated over a 18 months period.
Finally, a dermoscopic follow-up 24 months was registered for 156 acral nevi.
Substantial dermoscopic changes over 6, 12 and 18 months of follow-up were
observed in 5 (8.06%), 12 (12.77%) and 14 (22.22%) acral melanocytic nevi,
respectively. The most common dermoscopic pattern of the changing lesions was
the parallel furrow pattern (70.96%), followed by latticelike (9.67%), fibrillar
(6.45%), nontypical (6.45%) lobular (3.22%) and reticular pattern (3.22%).
Nineteen (61.3 %) of the changing lesions focally enlarged in size and were
surgically excised. None of the dermoscopic patterns changed to the multi-
component/malignant pattern, and all lesions excised were histopathologically
benign. In conclusion, we demonstrated that changes of dermoscopic patterns in
melanocytic nevi located in acral volar skin may occur in time, suggesting that in
some cases changes of dermoscopic patterns may reflect the biological evolution of
a specific lesion.
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Dermoscopic Changes of Melanocytic Naevi During the Pregnancy: Our
Experience
C Guerriero, C De Simone, I Proietti, A Paradisi, J Nowak, S Silveri-Lanza and R
Capizzi
Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy
A pigment naevus is benign proliferation of cells with melanocytic differentiation.
Embriologically, nevomelanoblasts are melanocytes within the neural crest. It has
been suggested that physiologic conditions, such as puberty, or systemic
corticosteroids, or human growth hormone therapy and pregnancy produces
changes in naevi. We aimed to document photographically any macroscopic and
dermoscopic changes of naevi during pregnancy. We followed twenty patients
before and at three, six, nine months of pregnancy. We observed appearance of
naevi resulting benign to histological examination (2/20) and changes of size and
some dermoscopic pattern in pre-existent naevi (18/20 patients).It is known that
pregnancy is marked by dramatic endocrinologic changes. Hyperpigmentation of
the areola, linea alba,axilla,and genitalia is commonly observed and well
documented during the pregnancy. An apparently related phenomenon is
darkening and enlargement of naevi, and several authors have suggested that
these clinical changes are accompanied by microscopic abnormalities. Our group
of patients isn’t large enough but new data acquisition during the time will allow us
to examine more closer the effects of pregnancy in naevi changes.
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Diagnosis of Non-Melanoma Skin Cancer with Optical Coherence
Tomography
M Mogensen and GBE Jemec
Department of Dermatology, University of Copenhagen, Denmark
Introduction. Optimal management of skin malignancies relies on early and
accurate diagnosis. Unfortunately the naked eye cannot always determine whether
a suspicious lesion is a non-melanoma skin cancer (NMSC). We have investigated
the diagnostic potential of optical coherence tomography (OCT) in NMSC.
Methods. The aim of this non-randomized, cross-sectional clinical study aimed at
enrolling 100 NMSC patients, is to investigate the diagnostic accuracy and
applicability of OCT in NMSC diagnosis. OCT-images will be compared to clinical
and histopathological diagnosis. OCT is analogue to B-mode ultrasound pulse
echo imaging with an optical rather than acoustical reflectivity being measured.
Imaging depth is 2 mm and axial image resolution is 9 micrometer. The OCT
equipment of this study was developed at Optics and Plasma Research Department,
Risoe, Denmark.
Results. The results from OCT-scanning of approximately 30 patients will be
presented. On the basis of pilot studies we expect to demonstrate a high sensitivity
and specificity in separation of malignant and premalignant skin lesions.
Discussion. A broad variety of diagnostic technologies are available for diagnosis of
NMSC. OCT has the capability of providing us with new, three-dimensional in
vivo, in situ understanding of NMSC development over time. In the future OCT
diagnosis could be used where standard excision biopsy is hazardous or
impossible, and perhaps reduce sampling errors associated with excision biopsy.
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Chromatin Assembly Factor-1 (CAF-1) Loss-of-Function: A Role in the
Deregulation of Cellular Proliferation in Skin Squamous Cell Carcino-
ma?
S Staibano*, G Fabbrocini1, M Mascolo*, G Salvatorey, M Di Benedettow,
C Mignogna*, E Mezza*, C Capasso1, M Mariano1 and G De Rosa*
*Department of Biomorphological and Functional Sciences, Pathology Section,
1Section of Clinical, Allergological and Venereological Dermatology Unit,
Department of Systematic Pathology, and ’Department of Medicine, ‘‘Federico
II’’ University, Naples, Italy
Recent studies outlined the role of CAF-1 as a novel useful marker of deregulation
of cell proliferation and prognostic indicator in human cancer and preneoplastic
lesions. CAF-1 is a heterotrimeric protein complex (constituted by p150, p60 and
p48 subunits) that delivers histones H3 and H4 to DNA during DNA replication and
DNA repair. Among the three CAF-1 protein subunits, the p60 protein acts mainly
on the control of the orderly progression of the cell-cycle. We studied by
immunohistochemistry CAF-1 p60 in a selected series of 40 cases of primary SCC of
the skin (10 G1, 20 G2, 10 G3). Results have been correlated with those concerning
the expression of proliferating cells nuclear antigen (PCNA) and with the main
clinico-pathological features of tumors. Our results indicated that CAF-1 p60 may
have a role as new prognostic marker in cutaneous SCC.
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Is Metallothionein – Overexpression Excelling Sentinel Lymph Node
Biopsy as a Prognostic Factor in Melanoma?
G Weinlich, G Topar, K Eisendle, P Fritsch and B Zelger
Clinical Department of Dermatology and Venerology, Innsbruck Medical
University, Innsbruck, Austria
Metallothioneins (MT) are ubiquitous, intracellular small proteins with high affinity
for heavy metal ions. Immunohistochemical MT-overexpression in paraffin
embedded tissues of patients with primary melanoma is associated with poor
prognosis. Sentinel lymph node (SLN) biopsy is an established surgical technique
for high risk melanoma patients with apredictive value for progression, whereas the
benefit for the individual patient´s overall survival remains unclear. We examined
the role of MT-overexpression in comparison with SLN biopsy in melanoma
patients as a prognostic marker for progression and survival. 158 patients
underwent SLN biopsy due to high risk melanoma. Primary melanoma specimens
were investigated by using a monoclonal antibody against MT on routinely fixed,
paraffin-embedded tissues. 28 (18%) out of 158 recruited melanoma patients
developed metastasis within the time of observation (median 37 months), 17 (11%)
patients died due to widespread disease. Kaplan-Meier curves gave significant
disadvantages for the MT-positive as well as the SLN-positive group for disease free
and overall survival. In the X2-test MT-overexpression was highly significant for
progression, whereas SLN biopsy failed significance. In univariate as well as
multivariate Cox regression analysis MT-overexpression turned out as an excellent
marker for progression (p¼0.007), the p-values for survival were not significant.
SLN biopsy did not show significant results for progression, but reached a p-value
of 0.03 in the analysis for survival. The results corroborate the validity of MT-
overexpression as a useful prognostic marker in melanoma patients which is at least
equivalent to SLN biopsy.
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The CDKN2A A148 T Variant is Not Associated with Melanoma Risk in
The French and Italian Populations
T Spica1, M Portela2, B Ge´rard2, F Formicone1, V Descamps3, B Crickx3,
L Ollivaud4, A Archimbaud4, N Dupin5, P Wolkenstein6, D Vitoux7, C Lebbe4,
P Saiag7, N Basset-Seguin4, MC Fargnoli1, B Grandchamp2, K Peris1, N Soufir2 and
Melan-Cohorty
1Department of Dermatology, University of L’Aquila, L’Aquila, Italy, 2Laboratoire
de Biochimie Hormonale et Ge´ne´tique, Hoˆpital Bichat-Claude Bernard, AP-HP,
Faculte´ de Me´decine Paris VII, IFR02, France; Departments of Dermatology,
3Hoˆpital Bichat-Claude Bernard, AP-HP, Faculte´ de Me´decine Paris VII, Paris,
France, 4Hoˆpital Saint- Louis, AP-HP, Faculte´ de Me´decine Paris VII, Paris France,
5Hoˆpital Tarnier, AP-HP, Faculte´ de Me´decine Paris V, Paris, France, 6Hoˆpital
Henri Mondor, AP-HP, Faculte´ de Me´decine Paris XIII, Cre´teil, France, 7Service de
Biochimie, Hoˆpital Saint-Louis, AP-HP, Faculte´ de Me´decine Paris VII, France,
8Service de Dermatologie, Hoˆpital Ambroise Pare´, AP-HP, Faculte´ de Me´decine
Paris-Ile de France Ouest, Boulogne Billancourt, France and yMELAN- COHORT, a
prospective cohort of melanoma patients constituted by all the University-affiliated
The A148 T polymorphism of the CDKN2A gene has been recently suggested to be a
low penetrance melanoma susceptibility allele in a population from Poland. To
determine the contribution of the A148 T variant on melanoma risk, we genotyped
this allele in 500 French melanoma patients (405 sporadic melanoma patients, 57
familial melanoma patients and 38 sporadic MPM patients), 119 Italian sporadic
melanoma patients and in 143 French and 121 Italian control subjects. For all
participants, age at melanoma diagnosis and data on melanocytic nevi were
collected and the A148 T allele was genotyped using the Taqman SNP Genotyping
Assay–allelic discrimination method. The frequency of the mutant allele A was 6.7%
in the Italian melanoma patients and 6.2% in the corresponding controls (OR 1.10,
95% CI [0.51–2.37]), 3.4% in the French melanoma group and 4.2% in the French
controls (OR 0.77, 95% CI [0.39–0.52]). No significant difference of the A148 T
allele frequency was observed between melanoma patients and controls in the
French and Italian populations, although the allele frequency was significantly
different between these populations (P¼0.008). No association of the A148 T allele
with melanoma risk was detected in the group of patients r 50 years of age at
diagnosis (French population: OR 1.53, 95% CI [0.41–1.55]; Italian population: OR
0.38, 95% CI [0.11–1.27]). In addition, in the French cohort, the A148 T was not
associated with any melanoma subgroup, i.e sporadic melanoma (allele frequency
3.4%, P¼0.88), familial melanoma (allele frequency 4.4%, P¼ 0.9). Our results
showed that the A148 T allele is not associated with the risk of cutaneous melanoma
nor with the age at melanoma diagnosis in the French and Italian populations.
P61
Lack of Association Between Cutaneous Melanoma, Breslow Thickness
and Vitamin D-Receptor FokI Polymorphism. A Case-Control Study
A Paradisi1, E Capoluongo*, MM Lavieri1, C Santonocito*, E Torti*, S Gentileschi^, A
Carbone1, T Sisto1 and R Capizzi1
1Institute of Dermatology, *Laboratory of Molecular Biology, Institute of
Biochemistry & Clinical Biochemistry and ^Plastic Surgery Unit, Catholic
University of the Sacred Heart, Rome, Italy
Background. Literature data reports an association between some Vitamin D
Receptor (VDR) polymorphisms and different kinds of tumors, including melanoma.
Only three VDR (FokI, TaqI and A-1012G) polymorphisms have been investigated
in association with the presence of cutaneous malignant melanoma (MM) or
metastasis development. FokI is considered the most important polymorphism
influencing the Vitamin D actions.
Aim. The present paper analyzes for the first time the association between FokI
polymorphism and melanoma prevalence together with Breslow thickness.
Materials and Methods. 101 MM and 101 healthy donors (belonging to Lazio
Region) matched for age and sex were enrolled. Molecular VDR typing was
performed by means of restriction length polymorphism analysis.
Results. All cases and controls were in Hardy-Weinberg equilibrium, FokI. No
significant associations between the FokI-ff genotype frequency and melanoma
patients and with Breslow thickness were found. In particular, only a significant
trend between FokI-ff genotype and Breslow thickness was observed.
Conclusions. Our work may be considered as the first Italian case-control study. Even
if the FokI-ff has been often associated to different neoplastic diseases or non
neoplastic diseases (diabetes, osteoporosis) our data are not in agreement with those
reported in the literature for the melanoma patients. In fact, these two recent paper
found a strict correlation between ‘‘ff’’ genotype and melanoma patients and ‘‘ttff’’
haplotype and Breslow thickness. These findings may be explained with the different
characteristic of populations analysed and with the control selection. Further
investigation, on a large number of cases, are necessary for a better comprehension
of the possible influence of the VDR polymorphisms in malignant melanoma disease.
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T Cell Responses Against Melanoma Associated Antigens in Patients
with Lentigo Maligna Treated with Imiquimod
RE Hunger, N Yawalkar and LR Braathen
Department of Dermatology, University of Berne, Inselspital, 3010 Bern, Switzer-
land
Imiquimod cream 5% has recently been described to be a potential treatment
option for lentigo maligna. This small synthetic molecule binds to toll like receptor
7 and induces the secretion of various proinflammatory cytokines such as IFN-g,
TNF-a; and interleukins leading to a strong inflammation of the skin. Little
information is available on the precise mechanism leading to destruction of the
melanoma cells in the epidermis. The aim of this study was to assess the
contribution of T cell-mediated immune reactions against melanoma specific
peptides. Patients with histologically confirmed lentigo maligna were HLA typed. 6
patients with either HLA-A01, A02 and/or B44 phenotype were included in the
study. All patients developed strong local inflammatory reaction of the diseased
skin after application of imiquimod cream. After therapy all patients were clinically
and histologically free of malignant cells. Using synthetic peptides presented by
these HLA molecules T cell reactivity were assessed before and after imiquimod
therapy by T cell proliferation assay and ELISPOT assay. Using PBMCs no specific T
cell response against these peptides could be detected before and after therapy with
imiquimod. In conclusion, the lack of specific T cell reactions in the peripheral
blood may indicate that no T cell reaction is generated or that the precursor
frequency is to low to be detected in our experimental system. Further studies are
required to see if specific T cells are locally present during the inflammatory
reaction.
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Downregulation of Chemokine Receptor Expression in Sezary Syn-
drome: Role of Extracorporeal Photopheresis
E Capriotti1, E Vonderheid2 and A Hess3
1University of Rome ‘‘Tor Vergata’’, Department of Dermatology, Rome, Italy,
2Johns Hopkins Medical Institutes, Department of Dermatology, Baltimore MD, US
and 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Department of Oncology, Baltimore MD, US
Introduction: Extracorporeal photopheresis (ECP) is an approved cell therapy for the
treatment of Se´zary syndrome, the leukemic variant of cutaneous T-cell lymphoma.
Despite the therapeutic benefit, the underlying mechanisms remain enigmatic. ECP
is associated with the production of immunomodulatory cytokines that can induce
tumor cell apoptosis. Anti-tumor immunity may also be enhanced by the
modification of the cytokine microenvironment augmenting the amplification of
effector T cells. Alternatively, ECP may modify the receptors expression on the
tumor cells that drive lymphocyte migration. Ongoing studies in our laboratory
suggest that Se´zary cells express high levels of CD62L (L-selectin) and CCR10,
CXCR3, CCR7, chemokine receptors involved in lymphocyte migration. The
present study examines the effects of ECP on the expression of these receptors.
Methods: Peripheral blood mononuclear cells were harvested from five patients (2
men, 3 women) with active Se´zary syndrome treated with ECP. Expression levels of
mRNA transcripts of these receptors were determined by real-time quantitative PCR
analysis.
Results: Gene expression of CD62L, CCR10, CXCR3, CCR4, CCR7 was significantly
decreased (100-1000 fold, po0.01) after the initial ECP. Similar results were
observed after the second ECP. In contrast, mRNA transcript expression of the
CXCR5 chemokine receptor and other T cell surface markers (i.e. CD4, CD28) were
not significantly altered.
Conclusions: These results suggest that the ECP leads to the specific down-
regulation of the CD62L, CCR10, CXCR3, CCR7 cell surface receptors. Such down-
regulation may limit the tumor cells ability to migrate into tissues and enhance the
targeting of the tumor cells by the immune.
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Molecular Demonstration of UVB-Induced Effects on Irradiated Nevi.
Impact of Sunscreens to Prevent Photodamage
C Carrera, S Puig, J Palou, M Lecha and J Malvehy
Melanoma Unit, Dermatology Department, Hospital Clı´nic de Barcelona,
University of Barcelona, IDIBAPS
Background: Sunscreens have shown a positive impact in the prevention of UVR
damage in keratinocytes. However their role in protecting melanocytes against
UVR has not been well established. We have previously developed a human in
vivo model to demonstrate the UVB-induced changes in nevi. We investigated the
expression of different molecular markers in irradiated nevi and the impact of
sunscreens.
Methods: Based on our in vivo developed model, twenty paraffined samples of 2
MED-UVB irradiated nevi were included. 7 days before excision, 11 nevi were
irradiated only on a half (physical protection on the other half), while in the other 9
nevi a physical and chemical sunscreen (octocrylene, Parsol 1789, titanium
dioxide, Mexoryl SX
TM
, Mexoryl XL
TM
) was applied on a half on each one before
irradiation of the whole lesion. Immunohistochemical stains were performed with
HMB45, MART-1, Ki67 and p53.
Results: Histopathological UVB-induced features were parakeratotic scale, and
mild lymphocytic perivascular inflammation. Most nevi showed increase size of
junctional melanocytes and their dendrites. Molecular changes were: 1) Notable
activation of melanocytes, both in the lesions and in adjacent skin (HMB45/
MelanA). 2) Increased number of proliferating cells, mostly lesional keratinocytes
(Ki67). 3) Mild increase expression of p53 in apoptotic irradiated keratinocytes, but
not in nevocytes. No differences were observed between physically protected areas
and sunscreen protected areas.
Conclusion: In addition to clinical and dermoscopical UVB-induced changes,
pathological and molecular effects were demonstrated in irradiated nevi. Molecular
differences were found between irradiated halves of nevi vs physically or sunscreen
protected areas.
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Novel Mutations of PTCH Gene in Asian: Two Case Reports of Basal Cell
Nevus Syndrome
T Chang-lin1, C Ying-jui1, S Lin-hui1, H Yu-ling1, H Cheng-hsiang2, T Chin-yuan3
and L Yang-chih4
1Department of Dermatology, Far-Eastern Memorial Hospital, 2Department of
Pathology, National Taiwan University Hospital, 3Department of Pathology,
Mackay Memorial Hospital and 4Department of Dermatology, Mackay Memorial
Hospital
The basal cell nevus syndrome (BCNS) is an autosomal dominant genetic disease
characterized by multiple basal cell carcinomas, odontogenic keratinocysts of
jaws, pitting of palms and soles, calcification of falx cerebri, and other
developmental skeletal abnormalities. PTCH (maps to chromosome 9q22), a tumor
suppressor gene, has been identified as the gene responsible for BCNS from 1996.
However, BCNS is quite uncommon in Taiwan as well as in Asia. We present two
Taiwanese BCNS males with two novel mutation sites, one C to T substitution in
exon 5 which results in premature termination at aa 135, and another G to A
substitution in exon 12 which resulted in premature termination at aa 602. In
addition, one of the patient had basal cell carcinoma at his nipple, which is an
unusual basal cell carcinoma presenting site in males. Under the dermoscope, the
nipple basal cell carcinoma showed patterns of branching streaks and some grey to
black globules, but no typical maple-leaf like patterns was seen. These patients
both received surgical treatment for basal cell carcinomas and followed up in our
clinics.
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Imiquimod Modulates the Expression of Survivin, Bcl-2 And Ki67 in Skin
Tumors
A Marconi, K Dallaglio, R Lotti, C Vaschieri, K Peris* and C Pincelli
Institute of Dermatology, University of Modena and Reggio Emilia, Italy and
*Department of Dermatology, University of L’Aquila, Italy
Survivin belongs to the family of inhibitor of apoptosis proteins (IAP) and it is
involved in regulation of cell death as well as cell division. It has been observed
that survivin is almost exclusively expressed in cancer tissues and in fetal stem cells,
but not in adult normal cell populations. Finally, as imiquimod has been used as a
proapoptotic agent in antitumoral therapy, we treated both squamous cell
carcinoma (SCC) and Bowen’s disease lesions with imiquimod for three months
and compared skin pathology before and after treatment. In SCC, survivin was
localized in scattered suprabasal keratinocytes, while in Bowen’s lesions it was
expressed in most suprabasal keratinocytes. In both neoplastic conditions, surviving
staining was at the nuclear level. Imiquimod treatment reverted the histologic
phenoytpe to normal survivin expression with cytoplasmic staining. In addition,
imiquimod normalize the expression of the anti-apoptotic protein bcl-2, which
appears to be mostly nuclear in SCC. In lesions from Bowen’s disease, bcl-2 is
expressed in basal and suprabasal keratinocytes, while it is detected only in basal
cells after treatment with imiquimod. Finally, imiquimod reduced the expression of
Ki67 in both SCC and Bowen. This study indicates that imiquimod modulates both
apoptosis and proliferation in skin tumors.
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Molecular and Functional Analysis of MC1R Receptor in Malignant
Melanoma
R Filotico, P Zanna*, C Danisi*, V Lattanzi, I Maida*, V Mastrandrea, N Cassano,
R Cicero*, GA Vena and G Guida*
Clinica Dermatologica II and *Dipartimento di Biochimica Medica, Biologia
Medica e Fisica Medica, Facolta` di Medicina e Chirurgia, Universita` di Bari, Italy
Pigmentation in mammals and cutaneous phenotype are due to the relative amount
of two types of melanins: pheomelanins and eumelanins. Brown/black eumelanins
are more photoprotective, and yellow/red pheomelanins are less photoprotective
and probably even phototoxic. The key enzyme for the melanogenesis is tyrosinase:
low tyrosinase levels mean that L-tyrosine is preferably converted to pheomelanins;
rising levels of tyrosinase push the melanogenesis versus the eumelanin synthesis.
AlphaMSH and its receptor MC1R are key regulation of cutaneous pigmentation
and tanning response. The human MC1R is highly polymorphic, and some of its
genetics forms are associated with various pigmentary phenotypes. Malignant
melanoma (MM) is a type of cancer due to both genetic predisposition and
environmental factors such as UV exposure. The genes involved in melanoma
development are of various type: high penetrance genes such as CDKN2A and
CDK4, and low penetrance one is the MC1R gene. In this study we obtained
primary lines of melanoma cell culture from South Italy Caucasian patients’
biopsies. We screened for their MC1R genotype, particularly in two different
melanoma cell lines, hmel 1 (from MM metastasis) and hmel 9 (from primary MM).
The MC1R sequencing revealed that the two cell lines analysed are homozygous
for the wild type receptor. These cultures showed histological and morphological
differences. Moreover, we demonstrated higher levels of the MC1R transcripts in
hmel 1 than hmel 9 cell lines. Functional analysis of MC1R receptor have been
performed. Endocellular cAMP level in response to alpha-MSH treatment has been
tested at different time of incubation. The cAMP assay revealed that the hmel 1 are
able to respond to the alpha-MSH treatment producing higher quantities of cAMP
within 15 min incubation in comparison to hmel 9 cell line. The tyrosinase activity
was very high in hmel 9 cell line and very low or absent in hmel 1. These different
behaviours of the two cell lines suggests that the cAMP pathway may be impaired
in certain human melanoma cells even when they express the wild-type receptor.
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Strategy for In Vitro and Ex-Vivo Testing of Neutrophins Signaling
Pathways Based on Immunoproteomic Array Profiling
P Atzei1,2, X Huang1, MC Fargnoli3, M Krajewska1, C Pincelli4, K Peris3, JC Reed1,
S-I. Matsuzawa1 and S Krajewski1
1The Burnham Institute for Medical Research, La Jolla, USA, 2School of
Biomolecular and Biomedical Science Conway Institute UCD, Dublin, Ireland,
3Department of Dermatology, University of L’Aquila, Italy and 4Dept of Internal
Medicine/Dermatology, University of Modena and Reggio Emilia, Modena, Italy
It is becoming apparent that p75NTR has a fundamental role in modulating TrkA
function. We initiated studies to disclose mechanisms by which p75NTR could
exerts the effects in epidermis and has relevance to BCC or melanoma
development. Unlike for neurons, the specific trophic ligands for p75NTR
modulation in keratinocytes or melanocytes have to be discovered. We established
the model for apoptosis in cells in which sortilin, a receptor ligand for p75NTR is
required for the pro-apoptotic activity. We used chimera extracellular receptor
CD4-p75 fused with transmembrane and intracellular domain of p75NTR to
stimulate the cells by anti-CD4 antibody. To identify the binding partners of
p75NTR we used GST- p75NTR cytosolic domain fusion protein to pull out
interacting death domains (DDs) from keratinocytes extract. To validate the in vitro
findings and to prove the hypothesis we combined in Tissue Microarray chips the in
vitro cellular preparations along with the patient surgical biopsies of 26 BCC and 24
of melanomas. This high throughput technology allowed us efficiently to screen for
expression signatures of multiple signalling molecules, which includes the status of
p75, sortilin, Traf2, Traf4, ITRAF, TRADD, RAIDD, PIDD, PAIDD, RIP-1, DR5, DR6
G3BP and many other proteins involved in apoptosis signalling pathways.
Automated evaluation of digital slide readouts is underway for identification of
statistically significant expression patterns with patient follow-up data. Although, it
is preliminary, the implemented strategy of in vitro experimentation in combining
with modern high throughput technologies examining wide cohorts of clinical-
pathological material, showed efficient progress toward planed aims.
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MAGE-A4 Staining Pattern Differs in Epithelial Skin Tumors of
Immunosuppressed and Immunocompetent Patients
B Muehleisen, L Schaerer, R Dummer, G Burg and GFL Hofbauer
Department of Dermatology, University Hospital Zu¨rich, Switzerland
The human MAGE gene family encodes proteins (Cancer/Testis antigens) which are
expressed in normal testis and in a variety of tumors. MAGE-derived peptides are
recognized by CD8þ T cells and represent targets for immunotherapy.
Monoclonal antibody 57B predominantly detects MAGE-A4 protein. Studied
mainly in melanoma, recent data suggest MAGE-A4 expression in epithelial
cutaneous neoplasms. Frequency of many epithelial skin tumors is increased in
immunosuppressed patients. We examined mAb 57B immunoreactivity in 119
formalin-fixed, paraffin-embedded specimens of epithelial skin tumors of actinic
keratosis, bowenoid actinic keratosis, Bowen’s disease and squamous cell
carcinoma (n¼17, 25, 61, 16, respectively) in immunocompetent patients
(n¼84) and organ transplant recipients (n¼ 35). Positive immunoreactivity was
defined as 5% or more positive tumor cells. In all positive samples, staining pattern
and polarity of immunoreactivity in the epidermis was assessed. Normal skin was
immunonegative. All four epithelial skin tumors showed comparable immunor-
eactivity (p¼ 0.361) ranging from 25% to 71% of samples. Absolute 57B
immunoreactivity was similar in the immunocompetent and immunosuppressed
group, but scattered staining pattern was more frequent in immunosuppressed
patients (p¼0.025). In squamous cell carcinoma there was a polarity of
immunoreactivity within the basal layer (p¼ 0.002) compared to intraepithelial
tumors. In conclusion, MAGE-A4 expression may help diagnosis and delineation of
epithelial skin tumors. Invasiveness of tumors seems accompanied by increased
MAGE-A4 expression on the leading cell front, possibly reflecting pronounced
anaplasia. Cancer antigen expression as judged by MAGE-A4 expression displays
subtle differences for organ transplant recipients only, suggesting other mechanisms
underlying the increased cutaneous carcinogenesis in these high-risk immunosup-
pressed patients such as TGF-beta and VEGF induction by calcineurine inhibitors.
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Survivin and Bcl2 Expression in CD30-Positive LPDs of the Skin
Compared to Systemic Anaplastic Large Cell Lymphomas
O Simonetti, G Goteri1, S Rupoli2, F Fazioli3, P Leoni2 and AM Offidani
Clinic of Dermatology, 1Institute of Pathology, 2Clinic of Hematology and
3Patologia Molecolare, Universita` Politecnica delle Marche, Italy
Cutaneous CD30-positive lymphoproliferative disorders (LPDs) are a spectrum of
disease ranging from lymphomatoid papulosis (LyP) to primary cutaneous
anaplastic large lymphoma (C-ALCL). Apoptosis is an active process regulating
cell population by programmed death and its deregulation plays an important role
in normal and malignant lymphopoiesis. We investigated the expression of two
inhibitors of apoptosis, survivin and BCL-2 protein, in 28 cases of T-cell CD30-
positive LPDs: 10 cutaneous CD30-positive LPDs (5 LyP, 5 C-ALC) and 18 systemic
ALCL. Immunohistochemical analysis was performed with antibodies against ALK1
protein, survivin and BCL-2 protein. RT-PCR studies for ALK and ALK/NPM were
performed on RNA extracted from paraffin blocks. All the cutaneous CD30þ LPDs
were negative for ALK by immunostaining and RT-PCR. Among systemic ALCL
cases, 7 were ALK-positive and 11 were negative: all the positive cases showed a
366 bp ALK transcript by RT-PCR and the specific NPM/ALK fusion transcript of 98
bp, ruling out the presence of a different rearrangement. All the cases examined
showed a cytoplasmic positivity for survivin. Five cases of systemic ALCL, ALK
negative, showed a nuclear dot-like immunoreactivity for survivin. Nuclear
expression of survivin was not observed in the other groups (X2: P¼ 0.045).
Protein BCL-2 cytoplasmic expression was found in 10 cases; systemic ALK-positive
ALCL show a lower frequency of BCL-2 expression (X2: P¼0.045). We can
conclude from our results that cutaneous and systemic CD30 positive disorders
show differences in survivin cellular location, suggesting that biological differences
among these groups might be related to an abnormal translocation of the molecule.
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Relapsed Actinic Keratosis Evaluation (R.A.K.E.) Study: Patients Char-
acterization and Clinical Management
S Chimenti1, A Giannetti2, D Crocetta3, S Biondi3, P Santoianni4 and the Rake study
group5
1Department of Dermatology, University of Study of Roma Tor Vergata, Italy,
2Department of Dermatology, University of Modena, Italy, 3Shire Italia spa,
Florence, Italy, 4Department of Dermatology, University of Napoli Federico II, Italy
and 5Dermatological Italian Sites
Objective: to evaluate the incidence and recurrence rate of actinic keratosis (AK)
relapses after 6 and 12 months from baseline and to describe the clinical features
and the management of patients affected by AK.
Design: multicentre, longitudinal, prospective observational study. Consecutive
patients, both men and women, referring to 10 Italian Dermatological Clinics, with
AK diagnosis underwent to medical interview where demographic and anamnestic
data were collected and a diagnostic assessment of AK and therapy prescription
were registered. Here we report data about baseline visit.
Results: a total of 216 individuals were analyzed. The majority of them (66%) were
men aged 7478 years (mean7 SD) while women were aged 75711 years. A total
of 150 forms of malignant neoplasia was registered; the 44% were basal cell
carcinoma and 23% were squamous cell carcinoma. The average number (7SD) of
AK skin lesions per patient were 4.3 (71.7). Most of these lesions were on scalp
(N¼ 309) and on face (N¼465). Diagnosisof AK was mainly performed through
only the observation (83%) or with the addiction of a dermoscopic assessment
(7.4%). The main prescribed therapy before the baseline was cryotherapy (10.8%)
and diclofenac (7.5%). At baseline, the majority of the prescribed therapy was
represented by topic therapy (47.2%) followed by phototherapy (14.9%).
Conclusion: these preliminary results show an interesting cross-sectional picture on
clinical features and management of the patients affected by AK. Further analysis
will be necessary at longitudinal phase in order to evaluate changes in the
management approaches of these patients.
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Relapsed Actinic Keratosis Evaluation (R.A.K.E.) Study: Clinical Changes
of Actinic Keratosis Lesions
S Chimenti1, P Santoianni P2, D Crocetta3, S Biondi3, A Giannetti4 and RAKE Study
Group5
1Department of Dermatology, University of Roma – Tor Vergata – Italy,
2Department of Dermatology, University of Napoli - Federico II – Italy, 3Shire
Italia spa - Florence – Italy, 4Department of Dermatology, University of Modena –
Italy and 5Dermatology Italian Sites
Aim: to estimate the incidence, regression and recurrence rate of actinic keratosis
(AK) after 2 and 4 months from baseline visit.Design: multicentre longitudinal
observational study. Consecutive patients, referring to 10 Italian Dermatological
Clinics, with AK diagnosis were enrolled. Here we report data about follow up at 2
and 4 months from baseline. Results: a group of 182 individuals were observed
after 2 and 4 months with a total of 763 AK lesions. The cleared lesions were 288
(37.8%) and 175 (22.9%) respectively after 2 and 4 months from baseline. Of these
lesions almost all were treated for about 2 months before the check at 2 and 4
months (87% Vs 98%). The percentage of persistency at 4 months was 32.5%,
while the recurrence rate was 6.8%, almost all of these lesions considered were
treated (94.4% and 96% respectively). After 2 and 4 months from baseline, 58 and
44 new skin lesions respectively were observed; the majority of which were on face
(48.3% and 47.7% respectively) or on scalp (31.0% and 38.6% respectively).
Nearly all the new lesions were diagnosed by only the observation (87.8% at 2
months Vs 93.2% at 4 months). Conclusion: little data are available on the AK
lesions evolution in Italian treated patients. These results show a preliminary
description of the distribution of AK lesions and of their clinical changes after two
observation (2 and 4 months), independently from the chosen therapeutic
approach.
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Epidemiological Survey on Melanoma in Two Central Italian Regions
(Abruzzo and Molise)
P Amerio, M Auriemma, F Morelli, A Tulli and the Study group on melanoma
Abruzzo e Molise: A Angelone, D Angelucci, MG Argentieri, L Artese, A Balboni, P
Bontempo, G Brandi, A Carbone, A Colasante, S Discepoli, C Fortunato, A Ieraci, G
Lettanzio, V Maccallini, G Orsini, M Palella, G Pizzicannella, G Proietto, L
Quaglione, G Sindici, L Vecchio and G Vitello
Clinica Dermatologica, Universita` Chieti-Pescara
Malignant melanoma is one of the most important skin tumour and its incidence
and mortality are increasing worldwide. Data on the incidence and prevalence of
MM in Italy are available through Cancer Registries but they do not cover all the
country. For this reason we set up an Epidemiological Survey on Melanoma (years
2002–2003–2004–2005) in two central Italian regions, Abruzzo and Molise not
covered by cancer registries. We screened both electronic and paper registry of the
all the Pathology departments of these regions for the key-world: Melanoma and
Malignant Melanoma. For each patients we collect data about: sex, age,
histological diagnosis and, if present, data about: localization, presence of
metastasis, infiltration, surgical margins. We exclude from our data-base all cases
of relapse of multiple melanomas diagnosed before 2002. We found 604
melanoma, 247 men (40.89%) and 357 women (59.11%). The case were divided
as follows: in 2002: 136 cases, in 2003: 173 cases, in 2004: 157 cases and in 2005:
138 cases. The theoretical incidence of melanoma in these two regions, thus, is
11.63 per 100.000 people-year in the period 2002–2004, which is similar to the
incidence registered in other southern Mediterranean countries. Melanoma affected
more often people aged 50–70 years (33.11%); the histotype more frequently
recorded is Superficial spreading (38.41%) and the majority (58.94%) were thin
melanoma (o1.00 mm). Also this data are in line with the international literature
data.
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Psychological Reactions after the Diagnosis of Malignant Melanoma
P Amerio, F Gambi&, B Battista*, M Auriemma, G Sepede&, D De Berardis&,
G Proietto, A Saggino$, FM Ferro&, D Abeni#, C Feliciani^, R Capizzi^, PL Amerio^
and A Tulli
Clinica Dermatologica, Universita ‘‘G. D’Annunzio’’, Chieti, Italy, &Clinica
Psichiatrica Universita` ‘‘G. D’Annunzio’’, Chieti, Italy, #Istituto Dermopatico
Immacolata, Roma, Italy, ^Clinica Dermatologica Universita` ‘‘Cattolica Sacro
Cuore’’, Roma, Italy, *Dipartimento di Scienze Biomediche, Facolta` di Psicologia,
Universita` ‘‘G. D’Annunzio, Chieti, Italy and $Dipartimento di Psicometria, Facolta`
di Psicologia, Universita` ‘‘G. D’Annunzio’’, Chieti, Italy.
Although malignant melanoma represents only 4 % of all skin cancers, it is the first
cause for skin cancer mortality worldwide. Prognosis of melanoma is linked to
histological and clinical characteristics (Breslow’s thickness and ulceration)
however it is frequently believed among health care providers and patients that a
good quality of life (QOL) may influence the course of the disease in these patients.
The efforts of coping with melanoma diagnosis and the ability to control feelings
may enhance depression and anxiety, in cancer patients may interfere with
treatment compliance and quality of life experienced by the patients. In order to
study the coping, psychological characteristics, and quality of life after the
diagnosis of melanoma and to determine if there are subgroups of patients that have
a different course of distress following the diagnosis, we submitted several
questionnaires to a cohort of melanoma patients after diagnosis and at different
time points over 1 year. The questionnaires included QOL measures and tests to
measure psychological features such as anxiety, expression and state of rage,
somatization, depression, self esteem and alexitymia. We found that the anxiety
state and the rage expression are elevated in these patients compared to normal
population although they do not reach the levels present in psychiatric patients.
The somatosensory amplification scale records levels are elevated compared to non
cancer subjects. Alexitymia is very high in melanoma patients to non cancer
patients and it seems that these levels correlate with an higher psychological
distress, somatization and rage.
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Pegylated Liposomal Doxorubicine in Classic Kaposi’s Sarcoma: a
Viewpoint
MA Montesu, MV Masala, R Satta and F Cottoni
Department of Dermatology, University of Sassari, Sassari, Italy
Doxorubicine is an antitumoral drug of the anthracyclinic class of antibiotics which
has been widely used in the treatment of solid and hematological tumors since the
1970s. In time, liposomal and pegylated formulation of the drug markedly
improved its farmacokinetic characteristics, reducing the notable toxicity levels of
conventional anthracylines and cumulative cardiotoxic doses. We report here the
use of pegylated liposomal doxorubicine in patients affected by classic Kaposi’s
sarcoma (CKS). A total of 5 HIV-negative patients, 4 males and 1 female, 3 of whom
had undergone previous therapies (Interferon, Bleomycine, Vincristine, Vinblastine,
Novelbine and Etoposide). All subjects were affected by generalized CKS: 4
presented notable edema of the lower limbs, 2 had genital lesions, 2 had lymph
node involvement, and 1 presented an anaplastic form of classic KS. All the patients
were given 20 mg/m2 every 21 days and the duration of therapy varied according
to how long it took for positive patient reaction (from 7 to 8 dosages). One patient
had complete remission of nodular lesions and all the remaining patients had
substantial improvement not only of clinical lesions but also of edema. These
findings, when we consider that these subjects all suffered from generalized CKS
and suffered only mild side-effects from the treatment, would lead us to support the
usage of pegylated liposomal doxorubicine in the treatment of CKS, alongside
traditional therapies.
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Topical Treatment of Cutaneous Pseudolymphoma –Report of Two Cases
FS Delli1, E Papadimitriou2, N Tsintros3 and starelos2
1State Hospital for Skin and Venereal Diseases, Thessaloniki, Greece; 2Agios
Dimitrios General Hospital Thessaloniki, Greece and 3Facolta` di Medicina,
Universita` ‘‘La Sapienza’’, Rome, Italy
Cutaneous pseudolymphoma refers to a heterogenous group of benign reactive
T- or B-cell lymphoproliferative diseases of the skin.
Two patients, each one with a single lesion, have been examined. A 74-year-old
man presented with a 6-month history of a pruritic tumor on the left arm after an
insect bite. A 56-year-old woman presented with a 5-year-history of a
papulonodular eruption on the face. Histology, immunohistochemical analysis,
T-cell receptor rearrangement analysis and immunoglobulin chain gene rearrange-
ment by polymerase chain reaction technique or by Southern blotting, confirmed
that the first lesion was a T-cell pseudolympoma and the second a B-cell one. The
first one was treated with daily topical application of pimecrolimus 1% cream and
the second one with triamcinolone acetonide 0.1% cream for 1 month. A follow-up
of six years showed no evidence of recurrence or any systemic disease.
Topical treatment for patients with single lesions of histological and immunohis-
tochemical diagnosed pseudolymphomas is considered easily accepted by the
patient, is effective and without important side effects.
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Primary MALT Type Skin Lymphoma –Is Wait and See a Possible Strategy?
FS Delli1, E Papadimitriou2, A Kostarelos3 and N Tsintros3
1State Hospital for Skin and Venereal Diseases, Thessaloniki, Greece; 2Agios
Dimitrios General Hospital Thessaloniki, Greece and 3Facolta` di Medicina
Universita` ‘‘La Sapienza’’, Rome, Italy
Primary Cutaneous Immunocytoma (Marginal Zone B-Cell Lymphoma) is
characterized by a proliferation of small lymphocytes, lymphoplasmacytoid cells,
and plasma cells, showing monotypic cIg on paraffin sections. In the REAL
classification they are classified as extranodal marginal zone B-cell lymphomas or
MALT type lymphomas.
We report a case of a 42-year-old white man with multiple subcutaneous tumors
located on the trunk and neck. The histopathological exam showed a non-
epidermotropic, dense lymphocytic infiltrate. Cytologically, the infiltrate was
polymorphous, mainly of B-cell phenotype with marginal zone B cells. CD20þ
cells were often observed. There was not present monotypic expression of light
chains. The bcl-2 mutation was absent. Investigation for other extranodal MALT
lymphoma gastrointestinal tract, lung, salivary and thyroid glands was negative.
The patient refused radiotherapy, but he accepted every 6 months close follow-up.
Over a five years period, we noticed a progressively disappearance of the skin
lesions. The necessity of aggressive treatment of this disease with excellent
prognosis is discussed.
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